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A. Executive Summary 
a. Overall summary of research study 
Past literature suggests that for elderly Heart Failure (HF) patients, an early initiation of Beta-
Blockers (BBs) can provide beneficial effects compared to Angiotensin-Converting enzyme 
Inhibitors (ACEI). This study compares the effect of these therapies for first HF 
hospitalization, recurrent HF hospitalization and for a composite outcome of HF 
hospitalization with death as the terminal event. The results support the effect of an early 
initiation of the therapies on these outcomes with a statistically non-significant effect of BBs 
compared to ACEI.  For BBs, the class effect was tested for sub therapeutic classes of BBs, 
i.e. BBc1 which includes bisoprolol, metoprolol etc. and BBc3 which includes carvedilol and 
labetalol. The results suggest BBc1 is a preferable therapy for the elderly (age≥65 years) HF 
patients compared to BBc3. 
b. Rationale 
HF imposes major health and economic burdens. To treat the disease, guidelines recommend 
initiating BB for stage B HF patients, i.e. the ones with mild/moderate HF as an add-on 
therapy after ACEI/ARB.  Despite this recommendation, some researchers argue that an early 
initiation on BBs could provide beneficial effects since BBs play an important role in 
reducing the risk of Sudden Cardiac Death (SCD) compared to ACEI.(Remme, 2007, 2008) 
Additionally, it has been proven that BBs have the ability for an early inhibition of cardiac 
remodeling, increased activation of renin-angiotensin system (RAS), greater anti-ischemic 
property and ability to achieve a higher dose.(Knight, Glynn, McIntyre, Mogun, & Avorn, 
1999) All these findings and facts substantiate studying the impact of initiating BBs in 
comparison to ACEI among elderly HF patients. Although randomized controlled trials 
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(RCT)s such as CIBIS III and CARMEN support this hypothesis,  the population included in 
these trials is at least 10 years younger compared to those existing in the community. These 
trials only concentrate on patients with EF<45% and they do not provide any class 
comparison of BBs with respect to ACEI. Additionally, these trials administer ACEI as a 
standard therapy in almost 90% of trials which creates a challenge to segregate the 
monotherapeutic effect of BBs from the effect of ACEI. Lastly, these trials have also been 
criticized for their inability to achieve optimum dose effects in the duration of follow-up. 
Considering these existing gaps in research, as well as cost, time and other resources required 
for gaining evidence from trials, motivates us to conduct this study. No other observational 
study has provided any such evidence in this regard. 
c. Objectives 
The aim of this study is to understand the impact of early initiation of different categories of 
BB compared to ACEI on the risk of HF hospitalization in elderly HF patients. The specific 
research objectives studied are: 
1. To find the Baseline Predictors of receiving ACEI vs. different categories of BB or 
the combination of two therapies in HF patients.   
2. To compare the time-to-first HF hospitalization across ACEI vs different categories of 
BB users or the combination therapy. 
3. To compare the time-to-recurrent HF hospitalization and composite outcome of time-
to-recurrent HF hospitalization with death as the terminal event across different ACEI 
vs different categories of BB users or the combination therapy as observed within a 
year of initiating a therapy.  
The hypothesis for this study is that the 3 clinical outcomes (time-to-first HF 
hospitalization and time-to-recurrent HF hospitalization and composite outcome of time-
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to-recurrent HF hospitalization with death as the terminal event) for the BB group are at 
least not significantly different compared to ACEI. 
d. Main findings 
1. An early initiation of a therapy has different predictors responsible for initiation of 
BBc1 or BBc3 in comparison to ACEI. 
2. The effect of early initiation of BBs is not significantly different compared to ACEI 
for the 3 clinical outcomes. 
3. For the included population patients, BBc1 seems to be a preferable therapy compared 
to BBc3 for the 3 clinical outcomes. 
e. Conclusions  
The risk of HF hospitalization varies non-significantly for BBs when compared to ACEI.  
There is a class effect of BBs on these outcomes with a favorable indication for BBc1 in 
comparison to BBc3. 
f. Impact of the study. 
The information from this study has multi-fold significance. 
1. For patients where ACEI is not tolerated, BBs can be an alternative therapy which can 
be considered to prescribe to initiate the treatment. In other words, the findings guide 
us towards some choice of making an individual-based judgment from amongst 
ACEI/ BB. 
2. The results are for the elderly HF patients with average age 73-75 years, as prevalent 
in HF community, whose frequency is less in the RCTs. In addition to this, the 
majority of the patients included in this study seem to have a normal Ejection Fraction 
4 
 
(EF). The information for this population is still a gap in the literature. Thus, the HF 
treatment scope is broadened in this study. 
3. If the results could be validated in further studies, an early initiation of BB can be 
considered for achieving a rapid inhibition of cardiac remodeling and thereby 
providing a better HF control. 
4. In addition to HF control, SCDs could decrease by an early initiation of BBs. 
5. The results seem to prefer BBc1 for the included population for HF hospitalization as 
the outcome in comparison to BBc3. Till date only guesstimates were being made 
about this information. But now there is some direction in this regard. 
6. The information is from real world data and has successfully teased out the effect of 
different categories of BBs from the influence of ACEI/ARB, which otherwise is a 
challenge in an RCT. 
7. The study estimates once validated will diminish the need to always conduct an RCT 
with ACEI as the standard therapy, which at times hinder the understanding of 
individual effect of new drugs under study in a trial.  
8. Lastly, in this study recurrent hospitalization has been estimated as a measure of 
Worsening of HF (WHF). This information in true sense establishes the equivalence 
of BBs with respect to ACEI. 
g. Introduction of the journal articles to follow. 
Three manuscripts discussed in the follow up journal articles are: 
1. Determinants of early initiation of ACEI vs BBs among elderly HF patients 
2. Risk of first HF hospitalization among elderly HF patients initiating ACEI vs BBs 
3. Risk of recurrent HF hospitalization among elderly HF patients initiating ACEI vs 
BBs  
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Manuscript # 1 
Determinants of early initiation of ACEI vs BBs among elderly 
HF patients 
 
 
Finding: The identified determinants related to initiation of BBs or ACEIs is the first step 
to determine which class of drug leads to better patient outcomes. 
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Abstract 
Objective: To estimate the determinants of initiating Beta-Blockers(BBs) vs. Angiotensin-
Converting Enzyme Inhibitor(ACEIs) among elderly Heart Failure(HF) patients. 
 Methods: Using Medicare Advantage Prescription Drug Plan for 2008-2011, elderly(age≥65 
years) HF patients initiating ACEI or a sub therapeutic class of BBs, defined as category 
1(BBc1 e.g. Metoprolol, Bisoprolol etc.) and category 3(BBc3 i.e. BBs with combined alpha 
and beta blocking activity e.g. Carvedilol and Labetalol), were identified. The baseline 
determinants of initiating either of the drug categories were identified by Multinomial logistic 
regression analysis using SAS 9.3 at the p-value of 0.05. 
 Results: Of all 6430 eligible patients, ACEI, BBc1, BBc3, a combination of ACEI and 
BBc1(ABC1), a combination of ACEI and BBc3(ABC3) or a therapeutic drug other than 
ACEI/BBs were initiated by 1194(18.57%), 1519(23.62%), 490(7.62%), 257(4.00%), 
126(1.96%) and by 2844(44.23%)  patients respectively. On average, patients were more 
likely to initiate BBc1 compared to ACEI or BBc3. This likelihood for initiating BBc1 
compared to ACEI increased statistically significantly by presence of atrial 
fibrillation/flutter(OR:1.348,95%CI:1.09-1.667), Age(OR:1.017,95%CI:1.005-1.028), with 
vasodilators(OR:1.373,95%CI:1.051-1.795) and with a missing BNP value compared to a 
Normal range of 0-99ng/L (OR:1.97,95%CI:1.085-3.578). For initiating BBc3 compared to 
ACEI the likelihood increased statistically significantly for males(OR:1.294,95%CI:1.039-
1.612), for patients with chronic atherosclerosis(OR:1.502,95%CI:1.12-2.015), for those 
taking vasodilators(OR:1.600,1.144-2.238) or Diuretics (OR:1.306,95%CI:1.05-1.625) or 
having an elevated value of BNP(OR:2.465,95%CI:1.008-6.029). It decreased statistically 
significantly for patients taking Calcium Channel Blockers (OR:0.718,95%CI:0.547-0.942) in 
the washout period. 
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 Conclusions:  The identified determinants related to initiation of BBs or ACEIs is the first 
step to determine which class of drug leads to better patient outcomes. 
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Introduction 
More than 5.5 million adults have heart failure (HF) in the United States, with an incidence 
rate of 10 per 1000 after 65 years of age and an estimated direct and indirect cost of HF of 
37.2 billion for 2009.(Shafazand, Yang, Amore, O'Neal, & Brixner, 2010) To treat the 
disease these guidelines recommend to use Beta-Blockers (BBs) as a stage B therapy for HF 
patients, i.e. as an add-on therapy after Angiotensin Receptor Enzyme inhibitors (ACEI) or 
Angiotensin Receptor Blockers (ARB). (Hunt et al., 2009) 
Contrary to this, some researchers argue that there is no need to always follow the dogmatic 
approach of ACEI before BB.(Cruickshank, 2000; Krum, 1999; Remme, 2008) They suggest 
that the reason behind ACEI being a preferable choice lies in the history of these trials. Till 
date, there exists ample of evidence in favor of ACEI compared to placebos which were 
collected decade before beta-blocker trials.(Chonchol, Benderly, & Goldbourt, 2008; de Boer 
& van Veldhuisen, 2008; Remme, 2007, 2008; Remme et al., 2004) As a result, ACEI 
became the first choice of therapy and it became an almost unethical standard to conduct a 
HF trial without prescribing ACEI as the standard therapy. For example, for beta-blockers, 
ACEI was part of approximately 90% of the trial’s patient population. This makes it hard to 
attribute the protective effect of the trial solely to beta-blockade. This research question and 
similar other research questions demands to assess, if we can change the on-going custom of 
not conducting a Randomized clinical trial (RCT) without always prescribing ACEI as the 
first-therapy of choice or can it be changed with other approaches like BBs.  And, while there 
is a lack of any guidelines for whether or not to conduct these RCTs, there is a need to take 
support of some alternative approaches like from observational studies that can answer these 
research questions. 
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As per an article by Remme et al, BBs play an important role in reducing the risk of Sudden 
Cardiac Death (SCD) compared to ACEI, thereby, BBs can be used as an initial therapy in 
elderly heart failure patients.(Remme, 2007, 2008) Further, the author recommends that BBs 
have an early protective effect on cardiac remodeling via the sympathetic system compared to 
ACEI effect on renin angiotensin systems (RAS). The SOLVD trial extends an early effect of 
BBs on RAS activation as well.(Knight et al., 1999) 
Based on these backgrounds, it becomes important to study the impact of initiating BBs 
before ACEI among HF patients on various clinical outcomes. If the abovementioned 
justifications holds true then it can be verified if BBs are more beneficial for elderly HF 
patients in comparison to ACEI. But before establishing this, it is of utmost importance to 
establish the factors that are associated with initiation of ACEI vs. BBs as monotherapy or as 
combination therapy. The information is crucial to establish the characteristics of sub-groups 
that differ in prescription of these therapies.  
Evidence from Randomized Clinical Trial (RCTs) and where do they lack 
The above mentioned hypothesis has been supported my many trials like CIBIS III, 
CARMEN trial, SENIOR trial, beta-PRESERVE trial and other RCTs like by Sliwa et al, 
which have proved comparable tolerability and other clinical outcomes like all-cause 
hospitalization, all-cause mortality etc. of different BBs with ACEI.(Flather et al., 2005; 
Komajda et al., 2004; Morrissey, Czer, & Shah, 2011; Remme, 2007, 2008; Remme et al., 
2004; Sliwa et al., 2004; R. Willenheimer, 2009; R. Willenheimer et al., 2005; Zhou et al., 
2010) These trials have established the beneficial effect of BBs mostly against Left 
Ventricular Ejection Fraction (LVEF). Efforts are still ongoing to establish its beneficial 
effect amongst patients with HF normal Ejection Fraction (HFNEF).  This means, a HF 
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patient, irrespective of his or her Ejection fraction (EF) can be hypothesized to benefit from 
BBs compared to or at least for their equivalence to ACEI.  
Additionally, studies have also reported that an effect of sub-therapeutic category (STC) of 
BBs. For example, COMET trial showed greater reduction in fatal and non-fatal MIs and 
SCD due to carvedilol treatment (Non-selective BB) compared to metoprolol treatment 
(Beta-1 selective agent).(Poole-Wilson et al., 2003) Moreover, physicians often tend to 
replace one drug with their therapeutic equivalent drug found in their class. This makes it 
important to understand this class effect. Although RCT is desirable across individual drugs, 
but considering its cost, time and other practical limitations, we cannot compare all BBs with 
all ACEI in a single trial or even in 2-3 trials. This implies that RCTs are an infeasible design 
approach to understand these class comparisons.  
Further, as already stated RCTs are not being conducted without prescribing ACEI as the 
standard therapy, this makes it difficult to differentiate the protective effect of BB w.r.t. 
ACEI.(Flather et al., 2005; Remme, 2007, 2008)  Apart from that the patients included in 
these trials are comparatively healthier and younger compared to real world data.(Jafar et al., 
2003; Remme et al., 2004) Thus, generalization of these study findings to the community 
tend to be a common issue associated with these studies.(Richardson et al., 2010) And even if 
the population matched that of community as in CIBIS-III trial, the experimental design 
approach tends to lose the proximity of the design findings to that of real world data. 
Moreover, this trial is not considered a good design to estimate the optimum effect of BBs 
due to its inability of not achieving the target dose. 
Evidence from the observational Studies 
Few worth noting observational studies compare the effect of ACEI vs BBs, but either the 
ACEI group has been combined along with some drug like ARB or used as an add on therapy 
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with other drugs like statins.(Richardson et al., 2010; Teng, Hung, & Finn, 2010) These 
articles either choose some specific population like after HF discharge or do not provide a 
head-to-head comparison.(Austin, 2009; DiMartino, Shea, Hernandez, & Curtis, 2010; 
Maison et al., 2012; Wijeysundera et al., 2011) The study by Toh et al has compared 
ACEI/ARB vs BB for different clinical outcomes like angioedema in a sample frame 
different than HF. (Toh et al., 2012) Similarly, study by Galindo-Ocana et al was not just 
restricted to HF patients only.(Galindo-Ocaña et al., 2012) Magid et al compared ACEI vs 
BB for Hypertensive patients.(Magid et al., 2010) All these studies indicate towards the need 
to compare BBs w.r.t. ACEI, thereby bringing more evidence for BBs. And if established as a 
standard therapy, then it would demand an increase in utilization of the BBs. However, some 
of the past literature suggests an underutilization of the therapy, which raises a doubt about 
the factors governing the utilization of the therapy in comparison to ACEI. The current study 
is an attempt to fill this gap in literature. 
Aim and Significance of the study 
With the given background, this study therefore aims to understand the determinants of early 
initiation of different categories of BBs compared to ACEI or the combination of both among 
elderly HF patients. For this, a cross-sectional observational study design on real world data 
from Medicare Advantage Prescription Drug (MAPD) Plan in Texas was used. Firstly, the 
study provides the information from population with average age 73-75 years, as is also 
prevalent in HF community.(Remme, 2008) Thus, this information is directly applicable to 
the community elderly HF population. Secondly, as already stated the information about 
determinants of initiating treatment gives an idea about the differential sub-populations 
whereby one drug is being preferred over other. A comparative effectiveness of these sub-
populations for different clinical outcomes can help to broaden the scope of HF treatment 
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among elderly patients for which ACEI is not tolerated. Thirdly, this study has brought 
evidence from real world rather than a controlled environment of a RCT and thus provides 
information from actual diseased patients of the community. This means a more reliable and 
generalizable information can be expected from the study. This shall also help us to tease out 
the effect of BBs from the influence of ACEI which is sometimes not possible in an RCT. In 
an article by Willenheimer et al, the author has suggested that the positive results of 
effectiveness shall provide the free choice of making an individual-based judgment from 
amongst ACEI/BB.(Ronnie Willenheimer, van Veldhuisen, Ponikowski, & Lechat, 2005) 
And thus, once there is sufficient evidence, it will not be required to always conduct an RCT 
with ACEI as the standard therapy, which at times hinders with the understanding of 
individual effect of new drugs under study in a trial.  The information from this study shall 
also be used in future studies whereby effectiveness shall be compared across these groups to 
establish aforementioned hypothesis. 
Thus, the specific aim of this study is to find Baseline Predictors of receiving ACEI vs. 
different categories of BB or the combination of two therapies in HF patients.  Predicted 
probability of receiving treatment with either therapy was calculated based on age, sex, 
clinical factors (Comorbid conditions and risk indices), co-medications used and certain lab 
values. 
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Methods 
This is a cross-sectional study on elderly (age≥65 years) HF patients enrolled in Medicare 
Advantage Prescription Drug Plan (MAPD) in Texas from the year 2008-2011. The data is 
collected by the Centers for Medicare and Medicaid Services (CMS).(Esse, Serna, Chitnis, 
Johnson, & Fernandez, 2013; HealthSpring, 2013). This claims data consists of several 
computerized data file that have information about patient membership, member summary, 
institutional claims, professional claims, Quest lab, CCMS and Part D Pharmacy Data.  
The membership file and the member summary file contain information about demographics, 
CMS risk score, cost, and type of visit or admission made in each month along with 
membership date and date of death information available for all claims. The Institutional and 
Professional claims files consist of information on inpatient and outpatient claims 
respectively. Whereas lab tests information can be obtained from Quest lab files, the 
Pharmacy files consists of drug identifying and related information like fill dates, days of 
supply, quantity dispensed and dosing information for each prescription filled. Information 
like admission reason (Elective, emergency, urgent etc.) and discharge date is obtained from 
CCMS file. 
The study is based on the CIBIS III design (R. Willenheimer, 2009; R. Willenheimer et al., 
2004) modified for observational studies based on other studies and aimed to use the design 
in future studies to compare ACEI and BBs for hospitalization as the clinical 
outcome.(Abbott, Trespalacios, Agodoa, Taylor, & Bakris, 2004; Chitnis, Aparasu, Chen, & 
Johnson, 2012; Magid et al., 2010; Richardson et al., 2010) The pictorial representation of the 
study design is presented in Fig 1. As is represented in the diagram, in future studies, these 
patients were followed for a year to observe the outcome. 
Ethical Considerations  
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This study is exempted from human studies review requirement by the Institutional Review 
Board of University of Houston. 
Study Sample 
The study sample includes patients from a stacked membership for the year 2008-2011 
(Figure 2).  All 10252 patients with CHF diagnosis were included for our study. This 
provides data for all HF patients in community, in long-term care facility or in hospice 
program and HF patients diagnosed by International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes 428.xx.(Richardson et al., 2010)  Past 
literature recommends that this method has >95% specificity for the diagnosis of 
HF.(Birman-Deych et al., 2005; Goff, Pandey, Chan, Ortiz, & Nichaman, 2000; Richardson 
et al., 2010) Along with this, the ICD-9-CM codes 401.x1, 404.x1, 398.91, 402.x1 and 
404.x3 are also recommended in the past literature for institutionalized Medicare 
beneficiaries and for those enrolled in a hospice.(DiMartino et al., 2010; Richardson et al., 
2010) Based on their CHF diagnosis date, which should be prior to initiation of either of the 
therapeutic groups, HF patients are included in the study. 
Inclusion criteria 
This study included any patient who after ‘01Jul2008’, had claimed for an ACEI or a ß-
blocker as monotherapy or in combination in the Pharmacy Data File.(Richardson et al., 
2010) These patients should have a diagnosis date of HF and a membership of at least 6 
months prior to initiation of either therapy. These 6 months prior to initiation of therapy was 
defined as the wash out period, whereby neither of ACEI/BB/their combination was 
prescribed. Although most of the past literature including CIBIS-III trial has considered a 
washout of 14days to 3 months; but based on a study by Shafazand et. al this study chose a 
washout of 6 months  for severity assessment of HF based on past hospitalizations and HF 
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utilization.(Shafazand et al., 2010; R. Willenheimer et al., 2004) A no prescription of either 
therapy was defined based on proportion of days covered (PDC) which as explained later was 
required to be less than or equal to 0.04. 
Exclusion Criteria 
All the HF patients with a recorded death or taking either ACEI, or BB category 1(BBc1) or 
BB category 3(BBc3), or a combination of BBs with ACEI or with each other in the washout 
period (i.e. PDC>0.04) were excluded. This does not include any patient taking Beta-blockers 
category 2 (BBC2) i.e. BBs with Sympathomimetic activity for 3 months prior to and also on 
the index date, due to their low sample size. Further, based on CIBIS III trial 
recommendation, any patient taking ARB, Aliskiren or aldosterone antagonist for 3 months 
prior to and also on the index date (i.e. PDC>0.04) was also excluded from the study, to 
avoid their potential risk of biasing the study.(Rashikh, Ahmad, Pillai, & Najmi, 2012; Toh et 
al., 2012) Pre-existing aldosterone receptor blocker was however permitted in the trial and 
also in this study. All the inclusion and exclusion criteria are represented in Fig 2. The 
patients with records after ‘05Jan2011’ were excluded from the study so as to include a 
patient with a possible 1 year record, which was used in further studies for comparative 
effectiveness. 
The study does not exclude the patients with possible contraindications to either drug in 
future, because despite possibility these patients were prescribed these therapies on the index 
date and thus needs to be accounted for on the index date. 
Index date 
This is the maximum date (Dmax) for an alive patient with age≥65 years from amongst the 
date of first drug supply claim (first dos), date of Heart Failure diagnosis (d(HF)), the date 
with at least 6 months prior membership (dm-6m) or a date that allows 6 months washout 
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with all inclusion exclusion criteria satisfied as mentioned above or a date on or after 01Jul 
2008.  
Prescription Drug Use 
Prescription drug use is reported in the Pharmacy Data file in the form of prescribed 
medication claims, with each claim corresponding to a single prescription fill for use till the 
recorded days of medication supply.   
The study used sub-therapeutic classes (STC) from pharmacy file identified and classified 
different therapeutic drug categories as per JNC-7 guidelines and various generic drugs 
including ACEI, BBc1 and BBc3.(Verdecchia & Angeli, 2003) The generic drugs included 
were as follows: (i) ACEI inhibitors included benazepril, captopril, enalapril, fosinopril, 
lisinopril, moexipril, perindopril, quinapril, ramipril, and trandolapril (ii) β-blockers included 
acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, labetalol, metoprolol, 
nadolol, penbutolol, pindolol, nebivolol, propranolol, sotalol, and timolol.(Abbott et al., 
2004; DiMartino et al., 2010) The BB categories included:  (1) Atenolol, betaxolol, 
Bisoprolol, Metaprolol, Nadolol, Propranolol and Timolol combined to define BBs as first 
category (BBc1). For this category no title has been defined except for Beta-Blockers. (2) 
Acebutalol, penbutalol, pindolol and nebivolol were classified as BBs with sympathomimetic 
activity (BBc2). (3) Carvedilol and Labetalol were categorized together in 3rd category of 
drugs with combined alpha- and beta- blocking activity (BBc3). Although ACC/AHA 2005 
guidelines approve all the above mentioned BBs, but it does not specify any classification 
scheme for the BBs, so a classification based on JNC-7 guidelines was adopted for this 
study.(Anderson et al., 2007; Verdecchia & Angeli, 2003) JNC-7 guidelines, provides non-
overlapping standard guidelines based therapeutic categories.(Verdecchia & Angeli, 2003) It 
also keeps bisoprolol/Metoprolol and carvedilol in separate groups which makes it possible to 
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compare these 2 drugs in separate categories, as required for comparative effectiveness and 
also recommended by past literature. (Poole-Wilson et al., 2003; Remme, 2007, 2008) 
Another crucial point that needs to be mentioned here is the fact that ACC/AHA 2013 
guidelines only recommend bisoprolol and metoprolol for BBc1 and Carvedilol 
forBBc3.(Yancy et al., 2013) However, considering the fact that other BB drugs are being 
utilized by MAPD data and additionally for various comorbidities associated with HF 
patients other BBs are recommended and being tested in various trials, all possible BBs 
mentioned above are being tested here.(Abbott et al., 2004; DiMartino et al., 2010; Hunt et 
al., 2009; Jessup et al., 2009; Pasternack, Pörsti, & Pöyhönen, 1982) 
Finally, after applying all inclusion/exclusion criteria 6 mutually exclusive drug use groups 
were created: (i) ACEI only; (ii) ß-blocker category I (BBC1) only; (iii) ß-blocker category 
III (BBC3) only; (iv) A combination of both ACEI and BBC1; or (v) A combination of both 
ACEI and BBC3; or (vi) No drug use from either category also termed as other therapies 
considering these patients may be taking some therapy other than ACEI/BBc1/BBc3.  
Combination therapy was defined as if the patient was taking prescriptions for 2 drugs from 2 
different categories on the index date.  
Proportion of days covered 
a) Required Drugs 
The prescription of a required drug i.e. ACEI, BBc1, BBc3 or their combination was defined 
based on the proportion of days covered (PDC) by these drugs defined by prescription date 
and the number of days supplied.(S. R. Leslie, Gwadry-Sridhar, Thiebaud, & Patel, 2008) 
Each drug was coded as ‘0’ for no drug and ‘1’ for the days for which the drug was 
prescribed. Thus, patient was defined to be on combination if the patient was coded as ‘1’ 
for ACEI along with either BBc1 or BBc3 on any day. If the patient was coded as ‘1’ for 
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only 1 of these drugs, then it was defined as a monotherapy of the particular drug. For 
example if ACEI is coded as ‘1’ but BBc1 and BBc3 are coded as ‘0’ then it’s a 
monotherapy of ACEI. If the patient was coded as ‘0’ for all these drugs, then it was defined 
as a patient getting some therapy other than ACEI/BBc1/BBc3. This strategy assures that 
patient was not misclassified as not taking a drug when he/she might have been prescribed a 
drug in some previous date to cover current date. Table 1 shows the respective number of 
drugs in each category. 
For excluding these required drugs, PDC was defined for the washout period. If a PDC > 
0.04 was observed, the observation was excluded from the study. For a PDC  0.04, patient 
was defined as taking 'no drug in washout' and thus was included in the washout.  
b) Not -Required Drugs 
For excluding the not required drugs i.e. ARB and BBc2, similar strategy was adopted. 
Initially, all the claims date and days’ supply information as available in the data set were 
used to define whether or not the patient received the drug on any day or not. If the PDCs 
covered by these drugs for 3 months within the washout period prior to the index date is  
0.04 then it was considered as a ‘no drug’ and thus this patient was included in the study. 
However, if PDC was more than this cut-off of 0.04 then it was called a prescribed drug and 
thus this patient was excluded from the study. Both these drugs along with aldosterone 
antagonists, aliskiren and spironolactone, defined as not required drugs, were again coded as 
‘0’ or ‘1’ for each day after the index date. If any of these not required drugs on the index 
date is coded as ‘1’, the observation was excluded from the cohort. 
c) PDC Cut-off Point (0.04)  
As stated previously, a cut-off point of 0.04 was defined to exclude patients from the 
washout period. This was done for a restrictive cut-off definition for not-required drugs. An 
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article by Chen et al suggests to keep a cut-off of 0.2 for a restrictive criteria for 
persistence.(Chen, Patel, Sherer, & Aparasu, 2011) This gives maximum allowable 
permissible days (MAPD) of 36days for 6 month washout period, which could easily include 
the whole month prior to the index date. To avoid this, an additional restriction was imposed 
on the month prior to the index date with a cut-off of 0.2. So, in all for the whole 6 month 
washout, a cut-off of 0.2 for 6 months and 0.2 for 1 month prior to the index date was 
defined. By law of multiplicative probability for independent events, this gives us a cut-off 
of 0.2*0.2 = 0.04.(Arora, Malhan, & ebrary Inc., 2010) This cut-off of 0.04 gives a MAPD 
of 7.2 days, much stricter restrictive criteria compared to previous 36 days. Additionally, the 
article by Funck-Brentano et al, a post-hoc analysis of CIBIS-III trial, also kept a MAPD of 
7 days, thus justifying the cut-off point of this study.(Funck-Brentano et al., 2011) The 
patients taking any of the not required drugs in the 3 months prior to the index date and on 
the index date were also excluded on a similar pattern i.e. PDC(3months)*PDC(1month) = 
0.2*0.2 = 0.04 which implies a MAPD of 3.6 days. 
In this study, each month was defined to have 30 days for consistency. This means a 6 
month wash period was of 30*6 = 180 days, 3month = 30*3 = 90 days and year of 12 
months = 30*12 = 360 days.  
d) Comedications 
Any comedications the patient might be taking on the index date were also coded as ‘0’ and 
‘1’ similar to each of the required drugs. However, considering the linearity distribution of 
the drug, if the PDC was ‘0’ then the comedications was defined as ‘No’ and else ‘Yes’. 
Sample Characteristics  
a) Socio-demographic Variables   
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These were obtained from member file and member summary files and included information 
about age, sex and county.(Ross et al., 2008) Using the frequency distribution of patients 
across County, patients across regions were classified as belonging to Gulf Coast, SE Texas 
and others.  All the insurance plans were classified as healthy advantage plans which 
includes some form of healthy advantage plan (Healthy advantage valley, Healthy advantage 
preferred,   Healthy advantage, Healthy advantage sadler, Healthy advantage sadler PR, and 
Healthy advantage select) and as total care category which includes other plans along with 
or apart from Healthy advantage plan (Total care, valley advantage plus Rx, advantage Plus 
Rx, City of Houston, Select, and Optimacare and also the ones with missing values). 
b) Severity  
The variables Disease State, fourth root of CMS risk score, log of cumulative cost observed 
for the treatment received in the washout period, prior hospitalization (DRG code 291-293) 
and duration of CHF diagnosis (<=0.25 years, 0.25-1year or > 1 year) were included as a 
measure of severity of the disease in the regression models.(S. M. Bernheim et al., 2010; 
Susannah M. Bernheim et al., 2011; "National average costs by department for heart failure 
and shock," 2010; Navarro-López, de Teresa, López-Sendón, & Castro-Beiras, 1997; 
Newhouse, Mills, Johantgen, & Pronovost, 2003; Ross et al., 2008; Suh, Hay, Johnson, & 
Doctor, 2012) The cumulative costs were expressed in national average annual consumer 
price index for year 2012 with more weightage given to recent month owing to their higher 
impact probability compared to services rendered 6 months back. (Statistics, 2012) The 
CMS score has been recommended by CMS risk adjustment methods for Heart Failure and 
thus has been used in this study.(S. M. Bernheim et al., 2010; Susannah M. Bernheim et al., 
2011)  
c) Comorbidities   
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The CMS co-morbidities as observed in the washout period were controlled using diagnosis 
codes from Institutional and Professional files based on their discharge date. This controls 
for history of Diabetes, hypertension (HTN), Coronary artery disease, Atrial 
fibrillation/flutter, chronic obstructive pulmonary disorder, Myocardial Infarction, Renal 
disease, CBVD/Stroke, Previous CABG surgery, Previous PTCA, Anemia, Peripheral 
vascular disease, prior percutaneous coronary intervention, pacemaker. (Susannah M. 
Bernheim et al., 2011; Li, Kim, & Doshi, 2010)  
d) Serum Markers   
The MAPD data also provides some of the lab values in the Quest file. Based on the 
recommendation by ACC/AHA guidelines and the systematic review by Ross et al, Blood 
urea Nitrogen (BUN), Sodium (Na), B-type Natriuretic Peptide (BNP), and Hemoglobin 
(Hb) as serum markers were also controlled.(Hunt et al., 2009; Jessup et al., 2009; Ross et 
al., 2008) For all the lab values, last observation which was carried forward (LOCF) as the 
observed value from the washout period was captured.(Sugihara, 2010) Additionally, BUN 
values were obtained from a product of BUN/Creatinine ratio and creatinine value.(Calabró, 
Willerson, & Yeh, 2003) For missing values of Hb, the tenth part of the product of MCH 
and RBC was used. If still missing, a conversion factor of 0.34 was multiplied with 
Htc.(Carneiro, Drakeley, Owusu-Agyei, Mmbando, & Chandramohan, 2007)  All these steps 
were taken because the lab values are not measured frequently as also suggested by 
Schneeweiss et al. And thus there were many observations for which no lab values were 
measured in the defined interval. So, in this analysis all the missing lab values were kept in 
the analysis under the category of 'Missing lab value', considering they could have some 
important information to understand compared to a normal lab value. Therefore, all the lab 
values were coded as normal values, abnormal value and missing value. The normal values 
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for all the markers were obtained based on clinical literature.(Calabró et al., 2003; Carneiro 
et al., 2007; Fonarow, 2008; Smith et al., 2010; Zairis et al., 2010) 
e) Baseline Comedications   
Diuretics (thiazide, loop, potassium-sparing and aldosterone-receptor blockers), Calcium-
Channel Blockers, Vasodilators and other comedications (Digoxin, cardiovascular agents, 
anti-arrhythmic, alpha-adrenergic agonist, alpha-blockers, Antiplatelet, Cardiac Glycoside 
and hypoglycemic medications) were controlled as comedications.(Ross et al., 2008; R. 
Willenheimer et al., 2004) As explained previously, these comedications were categorized as 
'Yes' and 'No' based on their PDC values in the washout period. 
f) Type of Physician  
The study also includes whether the patient visited a physician was associated with a local 
Physician Organization (LPO).(Wachter & Bell, 2012) Along with this, a visit to a physician 
paid for its quality i.e. P4Q flagged physician was also included in the analysis as 'Yes', 'No' 
variable to indicate whether or not the visit was made. 
All the variables were defined based on observed values for these variables in the washout 
period upto the index date. The transformations for CMS risk score and cumulative cost 
were done to bring the data distribution close to normality based on Q-Q plots for each of 
these variables across each treatment groups along with their respective 95% confidence 
interval.(LaLonde, 2012; Zhang, Chen, & Rain, 2004) For log transformation a value of '1' 
was added to the cost of '0' so as to make reasonable transformations.(LaLonde, 2012)  For 
age and log transformed cumulative cost no further transformations were done. 
Outcome: The probability of receiving either of the required drugs i.e. either ACEI or 
BBc1 or BBc3 or a combination of ACEI with BBc1 (ABC1) or with BBc3(ABC3) or a 
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therapy other than any of these therapies was the outcome for this study. Thus, it’s a 
multinomial outcome. 
Statistical Analysis 
The predictors were identified with the use of descriptive analysis and multinomial logistic 
regression, which aims to define the probability for prescription of 
ACEI/BBc1/BBc3/Combination/Other therapies. All analyses were performed using 
Statistical Analysis Software (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).  The 
final multinomial Logistic model was developed to get the final result with glogit link in 
Proc logistic and with statistical significance established at p-value ≤ 0.05.  
Sample Size requirement  
 Bisoprolol (BBC1) before Enalapril (ACE) - Monotherapy and their combination: 
In CIBIS-III trial, to demonstrate non-inferiority of bisoprolol-first vs enalapril-first, 450 
patients for per-protocol analysis enrollment was justified for a 95% Confidence Interval 
which should lie below the Hazard ratio of 1.125.(R. Willenheimer et al., 2004) The 
assumption made was bisoprolol-first group will reduce the primary end-point rate by at 
least 15% i.e. to 34%. This gives a probability of at least 92% at the 2.5% significance 
level (one-sided, two-sample problem, binomial distribution). And with a 10% drop-out 
rate, 1000 patients will be required. Further, for proving superiority of Bisoprolol (i.e. 
BBc1) w.r.t enalapril, to show a reduction of 25% in the bisoprolol group, the power to 
reduce event rate from 40% to 30% is 90% at 5% (2-sided test) significance level. In this 
study, with 505 patients in each group, at the end of monotherapy phase (6 months) the 
observed Hazard ratio (HR) for the WHF or all-cause mortality was 1.12 (95%CI: 0.77-
1.64, p-value = 0.54)(R. Willenheimer, 2009) Funck-Brentano et al suggested in a post-
hoc analysis of the CIBIS-III trial that being on monotherapy of either bisoprolol or 
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enalapril, with an HR of 39.7 (95%CI: 26.2-60.1, p-value <0.0001) was a statistically 
significant predictor of mortality and CV hospitalization as combined end-point compared 
to their combination therapy, with higher or lower doses.(Funck-Brentano et al., 2011) 
 Carvedilol (BBC3) vs. Enalapril (ACE) vs. Combination: With 159 patients on 
enalapril, 154 on carvedilol and 151 on combination therapy, the HR for All-cause 
mortality and all-cause hospitalization was 0.8403 and 0.5875 for Carvedilol and 
Combination therapy with enalapril as the reference category. For Carvedilol vs. 
combination therapy, HR was 0.7322. For WHF related hospitalization, the event rate 
was 8%, 6% and 4% for the enalapril, carvedilol and the combination group 
respectively.(Komajda et al., 2004; Remme et al., 2004) 
This means a sample of at least 500 patients per group is required and for combination group 
at least 160 patients are required. The table 1 shows the frequencies of each of the categories.  
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Results 
There were 6430 HF patients in the defined cohort from amongst 10302 HF patients from 
MAPD data. Frequency distribution of all the therapies in this cohort is represented in Table 
1. The table shows that therapies other than ACEI/BBc1/BBc3 are provided to most patients 
(44.23%) in the cohort followed by BBc1(23.62%). The combination therapies of BBc1 and 
BBc3 with ACEI, defined as ABC1 and ABC3, were prescribed to only 4.00% and 1.96% of 
the cohort population.  
Table 2 suggests that lowest mean age was 75.746 ± 6.66 for patients getting ABC3 and 
highest mean age was 77.386 ± 7.592 for group of patients getting therapies other than 
ACEI/BBc1/BBc3. The difference was statistically significant for patients initiating BBc1 
and other therapies compared to ACEI. On average patients had a mean CMS risk score in 
the range of 1.691-2.089, with highest CMS risk score being 2.089 ± 1.333,(0.304-8.464) and 
lowest CMS risk score being 1.691 ± 1.234 for the patients getting other therapies.  This risk 
score was statistically significantly different for patients initiating a combination of ACEI and 
BBc1 and for patients initiating other therapies compared to ACEI.  A long duration of CHF 
diagnosis with an average of 1.491±1.097,(0-4.977) may qualify a patient for ACEI 
prescription. The combination of ABc3 is preferred for high Count of past hospitalization 
(0.119±0.349,(0-2)) and high Log of cumulative cost of expenditure (9.355±0.788,(7.502-
11.111)) in the washout period, which are 2 measures of patients past severity upto the index 
date. These were followed by BBc3 with an average past hospitalization count of 
0.114±0.433,(0-4) and an average log of cumulative cost was (9.249±0.797, (5.978-11.524)).  
This cumulative cost was statistically significantly different for BBc3, its combination with 
ACEI and for other therapies. The average log of past cumulative cost was also on average 
high for BBc1(9.113±0.783,(6.004-12.021)) compared to ACEI(9.088±0.764,  (6.282-
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11.737)). However average count of past hospitalization was lowest for patients initiating 
BBc1(0.028±0.172,(0-2)). 
Table 3 suggests that on average, the cohort included more females (53.64%) compared to 
males (46.36%). Most patients belonged to Gulf Coast region (79.22%), had a form of 
healthy advantage plan (90.84%), had hypertension (57.947%), and visited a LPO flagged 
Physician organization (77.086%) with HF diagnosed for more than 0.25 years prior to the 
index date (68.383%). A very small percentage of the cohort population was diagnosed with 
normal lab values of BNP(1.633%), BUN(31.742%), LDL(22.675%), Hb(22.411%) and 
Na(49.114%). Not many of these patients were taking any comedications in the washout 
period including vasodilators (7.636%), calcium channel blockers (18.523%), Diuretics 
(32.613%) and other comedications (28.212%). 
Table 4 represents the frequency distribution of all the covariates across different treatment 
groups. They seem to follow the above results. Thus, apart from other therapies most males 
and females initiated on BBc1 on the index date and had high frequency of hypertension 
across all the treatment groups. Majority of patients with worsened HF hospitalization in the 
past initiated on some therapy other than ACEI/BBC1/BBC3(38.1%). Amongst ACEI and 
BBs, highest percentage of patients was initiating monotherapy of BBc3(18.45%) and 
BBc1(17.16%) had a worsened heart failure hospitalization in the washout period. As already 
stated, in all the treatment groups, majority of the patients were with LPO flagged physician 
during the month the drug was initiated. Of these, apart from providing therapies other than 
ACEI/BB(43.03%), the preference for prescribing BBc1 seem to be very high(23.89%). Even 
amongst patients visiting P4Q providers, the preference for initiating on BBC1 seems to be 
high(26.36%) compared to ACEI(22.11%) or BBC3(9.26%). Within a year of HF diagnosis, 
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patients were initiating other therapies. However, as the duration of HF diagnosis increases 
more percentage of patients were being prescribed BBc1(30.26%).  
Patients who took vasodilators or diuretics in the past washout period at any time point 
initiated on BBc1(34.01% and 29.03% respectively). If prescribed Calcium channel 
blockers(CCBs) in the washout, then highest percentage of patients(32.91%) initiated on 
Other therapies. With other co-medications, BBc3 was prescribed to 27.01% patients as the 
most preferable medication.  Patients initiating on ACEI, BBc1, ABC1 and other medication, 
diuretics was the highest prescribed co-medication in the washout period. Although the 
highest user percentage of diuretics was of patient initiating ABC3(61.11%), but all of these 
patients also received some other co-medication apart from vasodilators, CCBs or diuretics. 
Like ABC3 group, all of BBc3 users also received these other co-medications i.e. 100% of 
them got these other co-medications along with a very high percentage of diuretics(46.74%).   
Table 5 represents the predictors of initiating on each of the therapies.  
1) BBC1 vs. ACEI 
 Monotherapy (BBC1) 
The odds for initiating BBc1 therapy as opposed to ACEI increases statistically significantly 
amongst patients with Pneumonia (OR: 1.321; 95% CI:1.028 - 1.698), Trauma in last year 
(OR: 0.74; 95% CI: 0.598 - 0.917), taking Vasodilators  as co-medication in the  washout 
period (OR:1.382, 95% CI: 1.055 - 1.811) and having a Missing BNP Value vs Normal 
value which is in range from 0-99ng/L (OR: 1.982, 95% CI: 1.089 - 3.607).  It increases by a 
multiple of 1.018 (95% CI: 1.006 - 1.05) for each unit increase in age. 
 Combination of BBC1 with ACEI (ABC1) 
For patients with Mental Disorder and Acute Myocardial Infarction the odds of initiating 
ABC1 instead of ACEI increases by 1.533(1.022 - 2.3) and 1.798(1.103 - 2.928)times. It 
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also increases by 1.467(1.108 - 1.943) times for patients being prescribed Diuretics in the 
washout period but decreases by 0.619(0.411 - 0.931) times after a year of Heart Failure 
(HF) diagnosis compared to if HF was diagnosed 0-3 months prior to initiation of any of 
these therapies  on the index date. 
2) BBC3 vs. ACEI 
 Monotherapy (BBC3) 
The odds of initiating BBc3 therapy as opposed to ACEI while being a male or a patient 
with Chronic Atherosclerosis, taking Vasodilators  or Diuretics (Yes vs No) or if 
hospitalized with worsened HF are 1.293(1.034 - 1.617), 1.69(1.231 - 2.321), 1.625(1.156 - 
2.284), 1.293(1.037 - 1.613) and 2.196(1.342 - 3.593) respectively times higher compared to  
their reference category. These odds of initiating BBC3 compared to ACEI decreases by 
0.719(0.546 - 0.946) times if the patient was taking Calcium Channel Blockers (CCB) 
compared to the one not taking them.   
 Combination of BBC3 with ACEI (ABC3) 
The odds of Gender (Male vs Female), chronic atherosclerosis, Rheumatic fever (Yes vs 
No),  Log of cumulative cost, Diuretics (Yes vs No) and if patient was hospitalized with 
worsened heart failure increased statistically significantly for the patient initiating ABc3 
therapy as opposed to ACEI as follows: 1.817(1.213 - 2.721), 1.944(1.088 - 3.473), 
2.224(1.049 - 4.712), 1.554(1.118 - 2.158), 2.675(1.802 - 3.971)  and 2.568(1.233 - 5.351) 
respectively.  The odds of CCB (Yes vs No), initiating ABc3 therapy as opposed to ACEI 
decreases by 0.402(0.223 - 0.725) units. 
3) Other Therapies vs. ACEI 
The odds of having Pneumonia (Yes vs No), Metastatic Cancer (Yes vs No) or 
Cardiorespiratory Failure and shock , Disease State (Disabled/ESRD/Hospice/Institutional 
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vs Medi/Medi), Age, LDL (Abnormal vs Optimal: <100mg/dL),  LDL (Missing Value vs 
Optimal: <100mg/dL) for patients  initiating other therapy as opposed to ACEI are 
1.426(1.121 - 1.814), 2.673 (95%CI: 1.7 - 4.202), 1.61(1.246 - 2.082), 2.342(1.336 - 4.104), 
1.02(1.009 - 1.032), 1.56(1.214 - 2.006) and 1.616(1.276 - 2.046) respectively. 
The odds of initiating Other Therapies compared to ACEI decreases if the patient was 
diagnosed with Anterior Myocardial infarction (Yes vs No) or had PTCA (Yes vs No) in the 
washout period by 0.686(0.485 - 0.971), 0.688(0.475 - 0.997) respectively. These odds 
further decrease by  Duration of HF (0.25-1 yr. vs <=0.25 yrs.), Duration of HF (> 1 yrs. vs 
<=0.25 yrs.), taking Vasodilators  (Yes vs No), CCB  (Yes vs No) or Diuretics (Yes vs No),  
or if the patient's last visit was with a physician with a P4QFlag by 0.151(0.12 - 0.189), 
0.1(0.08 - 0.125), 0.526(0.384 - 0.72), 0.582(0.481 - 0.705) and 0.484(0.411 - 0.57) 
respectively. There is also an observed decrease on odds of initiating Other Therapies by 
0.772(0.678 - 0.878) units for per unit increase in Log of Cumulative cost and by 0.52(0.428 
- 0.632) for patients visiting Physicians paid for quality or by 0.612(0.419 - 0.893) if 
belonging to SE Texas Region vs. others. 
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Discussion 
Although the guidelines and RCTs prefer ACEI to be a preferred therapy for Stage A HF 
(mild HF or patients at risk of HF), but in this study a large proportion of patients was not 
getting this therapy. This indicates that the cohort in this study includes patients for other HF 
status as well. This highlights the importance of understanding the severity state of the 
patient before prescribing or adding a therapy. Interestingly, against guidelines 
recommendation of BBs as an add-on therapy, many patients were on BBs as monotherapy 
(31.24%) i.e. without ACEI. Past literature suggests that BBs are an underutilized therapy 
but its use is increasing.(Komajda et al., 2004; Richardson et al., 2010) This could possibly 
explain the observation of high percentage of patients on BBs as monotherapy. And as 
already stated RCTs find it difficult to prescribe BBs as monotherapy, this study is a good 
alternative to study the factors associated with an early initiation of these therapies.  And 
thus, the results in this study can provide good directions for future studies. 
Additionally, as can be observed in the results that age variation for this study across all the 
treatment groups is same as that existing in the community (75-77 years) which again is a 
challenge for a RCT but has been captured here. Hence, these results are a better 
representative of the community population. The results indicate that there was a statistically 
significant variation in baseline age for BBc1 compared to ACEI which also proved to be a 
significantly high risk factor for increasing odds of initiating BBC1. For BBc3 also the 
likelihood was towards non-significantly high. This could be possible evidence based 
prescription of ACEI as per past trials like SENIOR, which recommends BBs to be safe 
drugs for elderlies.(Flather et al., 2005) 
Since the aim of this study is to find the predictors of initiating BBs compared to ACEI, the 
study has focused on the results for ACEI vs BBs as monotherapy or as combination only. 
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These results indicate that irrespective of the gender and region, majority of the patients 
were initiating BBC1 as monotherapy. A combination of ACEI and BBC3 was prescribed to 
lowest percentage of population in any region. Probably severe cases are getting BBC3 as 
monotherapy or as combination as a preferable drug. And such cases are selective cases with 
low frequency in any region.  In CARMEN trial authors have argued that BBs are under-
utilized therapy being only 8%-37% in hospital setting and especially may not be a 
preferable choice for mild CHF patients attributable to the fear of their side-effects unknown 
in this population. Many other observational studies like Richardson et al and Toh et al also 
reported under-utilization of BBs, however all these studies included the patients with severe 
HF.(Richardson et al., 2010; Toh et al., 2012) This demands to further explore this 
population for their possible clinical risk with BBs and side-effects especially among 
patients with mild HF. 
Although CMS risk score of the month a therapy was initiated seemed similar across all 
groups,  on average it was highest across BBC3 initiators, which may indicate that BBc3 are 
prescribed in severe cases compared to ACEI. Despite this possibility, it was not a 
statistically significant predictor for initiation of BBc3 or BBc1 compared to ACEI. 
Therefore, it can be concluded that although high but not much variation w.r.t CMS risk 
score was observed in this study. Here, a reverse causation tendency cannot be neglected, 
which means because these therapies were given a high CMS risk score was observed in the 
month these therapies were initiated. For this further exploration of the effect of these 
therapies on various clinical outcomes need to be established.  
The study has included other severity measures like the past hospitalization and cumulative 
cost in the washout period which again were found to be higher for BBc3 and ABC3 
compared to ACEI and thus they again indicate plausibility that at least BBc3 are prescribed 
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for severe cases.  Even for patients initiating BBc1, of all past hospitalization 17.16% 
belonged to this group compared to 18.45% for BBc3. But unlike BBc3, the likelihood of 
initiating BBc1 with these past hospitalizations was non-significantly low compared to 
ACEI. Further for all these groups, the odds ratio decreases with increasing duration of HF 
diagnosis, which means the odds of prescribing ACEI increases as the duration of HF 
increases. These contradictory results amongst different measures of severity indicate a 
possible lack of understanding of severity measures w.r.t. BBs not only just from current 
clinical point of view but also from past health status and past economic status.  This could 
be important for exact correlation of severity measures and therapy initiation.  
CIBIS III trial found a correlation between LVEF and past non-cardiovascular 
hospitalization and concluded it might not be of clinical significance.(R. Willenheimer et al., 
2005) The trial recommends that for mild to moderate CHF patients and for those with 
impaired LVEF, the rates for death and all-cause hospitalization as composite outcomes 
were similar for bisoprolol (BBc1) and enalapril. The CARMEN trial included patients with 
LVEF <40% and recommended carvedilol (BBc3) as a safe therapy to initiate compared to 
ACEI.(Komajda et al., 2004) Similarly, in a trial by Sliwa et al, the authors recommended 
that carvedilol(BBc3) leads to better improvement in LVEF and reduces NYHA functional 
class compared to ACEI.(Sliwa et al., 2004) Another trial, Beta PRESERVE is on-going to 
recommend metoprolol for HF patients with normal EF.(Zhou et al., 2010) All these trials, 
irrespective of EF i.e. severity level, together see potential in initiating BBs compared to 
ACEI. Similar to these trials our study found CMS risk score, a direct indicator of severity 
for claims data, to be high but non-significant predictor.  However, past hospitalization was 
significant for BBc3 and ABC3, past cumulative cost for ABC3 and duration of HF for 
ABC1. These varied measures of severity were not explored in the previous trials. 
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As stated earlier, irrespective of gender, BBc1 was being initiated in majority of population. 
Contrary to this, being a male has a significant positive effect on increasing the odds of 
initiating BBC3 or its combination with ACEI; whereas it has a non-significant negative 
effect on initiation of BBC1 or its combination with ACEI. The CIBIS III and CARMEN 
trial also included majority of males, 68.22% and 80.66% respectively.(Komajda et al., 
2004; R. Willenheimer et al., 2004) However, they did not explore if that could be the 
reason to see beneficial effects in their population. Similar to this SENIOR trial also 
included majority of males(females 37%) and found that for nebivolol(BBc1) vs placebo 
there was no significant effect of gender on composite outcome of all-cause mortality and 
cardiovascular hospitalization, thereby supporting our study.(Flather et al., 2005) 
The study also demonstrates the effect of comorbidities on initiation of a therapy. The 
results indicate that the patients diagnosed with Pneumonia and Last year Trauma preferably 
initiate a BBC1 therapy, with Acute Myocardial Infarction and mental disorder they prefer 
to initiate on a combination of ACEI and BBC1, with chronic atherosclerosis initiate BBC3 
and its combination ABC3. The latter is also initiated if the patient had Rheumatic fever in 
the washout period. In a study by Richardson et al, the author has suggested that although 
previously denied recent data support the use of BBs for COPD patients provided they are 
up titrated carefully and dose is lowered for any observed bronchoconstriction.(Richardson 
et al., 2010) Interestingly, our results also indicate that although likelihood is low for 
initiation of BBs but despite that COPD is not a significant predictor for prescription of 
ACEI or BBs. 
Authors from OPTIMIZE-HF trial reported Pneumonia to be one of the crucial factors for 
precipitating HF hospitalization with Odds ratio 1.60 and they stated that it significantly 
increases length of stay and in-hospital mortality.(Fonarow et al., 2008) The study by virtue 
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of IMPACT-HF trial, COMET trial and also from the findings of their study reported that 
pre-discharge initiation of beta-blockers was associated with a higher rate of β-blocker use 
after hospital discharge and significantly lower risk of post-discharge mortality for 
decompensated HF, with no increase in hospital length of stay and risk of worsening of 
HF.(Fonarow et al., 2008) None of these trials associate the impact of individual therapy or 
class therapy effect with HF hospitalization due to Pneumonia. A recent study by Soto-
Gomez et al recommends the need for more studies to establish the beneficial effect of 
cardio protective medications for patients hospitalized with Pneumonia.(Soto-Gomez, 
Anzueto, Waterer, Restrepo, & Mortensen, 2013) In this regard, our study could be one of 
the initial evidence to establish an association between HF patients hospitalized for 
Pneumonia and prescribing BBc1. For post-trauma, propranolol (BBc1) is an evidence-
based therapy recommended by international consensus meeting of experts for revising 2005 
psychopharmacology guidelines for British Association for 
Psychopharmacology.(Pasternack et al., 1982) Ample of literature exist that recommend 
prescription of ACEI and Beta-blockers together.(Fahey, Brindle, & Ebrahim, 2005; Gupta 
& Aparasu, 2013; Sleight, Pouleur, & Zannad, 2006; Wald & Wald, 2010; Wise, 2005) 
Evidence also exists to support the use of BBc1 drugs like propranolol and timolol and bbc3 
drug carvedilol for Post-MI treatment.(Gheorghiade & Goldstein, 2002)  The study although 
did not provided a direct head-to-head comparison of the effect of type of BB on clinical 
outcomes, but it pooled the findings from BHAT, NORWEGIAN and CAPRICORN trial for 
respective drugs and reported less percentage incidence rate of all-cause mortality, sudden 
death and composite outcome of mortality and reinfarction for propranolol compared to 
carvedilol and timolol. Only Non-fatal reinfarction rate were lower for carvedilol. This could 
be the reason for favorable effect of ACEI with BBc1 as reported in our study. It is reported 
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that for mental patients the therapies for other comorbidities including cardiovascular 
therapies are generally underutilized.(Mitchell, Lord, & Malone, 2012)  In our cohort only 
19.4% had mental disorders of which 53.06% were getting either ACEI or BBs. This 
appears to be pretty high percentage compared to past literature which demands quality care 
even amongst patients with mental disorder. For atherosclerosis, HF guidelines do not state 
anything about treatment with BBs but recommend only for ACEI for such patients.(Yancy 
et al., 2013) However, an article by Fonarow et al recommends carvedilol for the 
atherosclerosis.(Fonarow, 2009) And in another trial by Drexel et al, the study found that 
bisoprolol appears to decrease the lipid mediated risk of developing or accelerating chronic 
atherosclerosis.(Drexel, Schmid, Follath, & Amann, 2001) Based on a brief review of past 
literature, a direct comparison between bisoprolol and carvedilol is not available. If that is 
the case, then our results again provide research direction for future research, which 
recommends not only a significant association between BBc3 and chronic atherosclerosis 
w.r.t. ACEI as monotherapy and as combination with ACEI but it also provides a non-
significant association between BBc1 and chronic atherosclerosis w.r.t. ACEI thereby 
establishing BBC3 to be superior to BBc1 and ACEI both. For Rheumatic Fever, in a study 
by Shu et al, the authors attributed positive effects of bisoprolol(BBc1) to non-vasodilatory 
effect of the drug compared to BBc3 which has vasodilatory effect to worsen lower cardiac 
output.(Shu et al., 2005) Our study showed a higher non-significant odds ratio for initiation 
of BBc1 compared to BBc3 with ACEI as the reference drug, thus supporting the argument 
made by Shu et. al.(Shu et al., 2005)  However, at the same time with the addition of ACEI, 
results reverse and thus it leads to significantly higher initiation odds ratio for BBc3 and 
ACEI w.r.t. ACEI.  
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A large portion of lab values was missing even after carrying forward the last observation 
(LOCF), as also suggested by Schneeweiss et al.(Schneeweiss et al., 2012) These missing 
values could have some reason for being missing, primarily if the physician had no reason to 
believe that some lab value may be high then treatment will proceed with the assumption of 
a normal lab value. However, logistic regression indicates that the missing values had a 
significant impact on prescription of these treatments. This recommends keeping a close 
watch on patient lab values. Deleting this information would have led to omitted variable 
error and this would have also tampered with the sample size of the data and hence the 
results would have been biased. Although, now we just are able to provide the information 
that missing lab values had a significant impact on prescription of these therapies but this 
information suggests capturing it in future as it could be an important group. Information 
about BNP is an important factor in increasing the odds of initiating BBc1. An elevated BNP 
or a missing value of BNP had a significant increasing effect on initiation of BBc1 and a 
non-significant high effect on odds of other BBs. This means BNP information should be 
captured as frequently as possible to decide if BBs are required. 
While interpreting these results it is to be kept in mind that although the study has suggested 
that patients were initiating on certain therapy on the index date, but it is possible that 
patients might have been taking certain therapies other than ACEI or BBs before and also on 
the index date. These therapies have been defined as comedications that patient might be 
taking apart from the therapy initiated by him/her on the index date. The results indicate that 
prescribing Vasodilators and Diuretics increase the odds of prescription of BBC1 or BBC3, 
while CCBs tend to decrease this odds ratio. As per ACC/AHA guidelines, Diuretics and 
Vasodilators (Hydralazine and Nitrates) are recommended for Stage C i.e. for mild to severe 
HF patients.(Shafazand et al., 2010) This implies that in real world all severe patients are 
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being preferred BBc1 or BBc3 compared to ACEI. If this is true and also since other 
predictors of severity showed similar trend then an important research question that should 
be explored in future is that if initiating BBs in mild to moderate HF patients could be 
beneficial in any sense compared to ACEI. In other words, there is a need to understand if an 
early initiation on BBs is beneficial compared to ACEI. This is exactly what trials like Beta-
PRESERVE are trying to establish and is being discussed by many authors and has been 
mentioned previously in this study. 
An interesting observation is that although most of the physicians visited were local 
physician, majority of them were not P4Q flagged. This may be probably because, still there 
is a lot of debate on-going regarding whether or not physicians should be paid for quality as 
a measure of their performance. As per an article by Esse et al, various quality compensation 
programs although appear promising, they are yet to yield encouraging results and thus 
continue to hold debatable status in current scenario.(Esse et al., 2013) Both P4Q flagged 
physician or a LPO flagged physician (discarded during the optimization process) seems to 
have a non-significant effect on initiation of any of the BBs compared to ACEI. This means 
the initiation of any of the BBs compared to ACEI does not significantly vary across type of 
physician.  
Limitation 
1. The study is a claims database study and thus all the issues like under coding and 
upper coding of disease are inherent to this study. 
2. The study has used Prevalent HF patients, which could be at different stages of their 
disease. Although, by a washout period of 6 months, only the incident drug users were 
included, but again the study does not discriminate if ACEI vs BB vs combination 
was used as first line or 2
nd
 line or 3
rd
 line therapy. As already stated, these patients 
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may not be taking these required drugs in the washout period but they may be taking 
some drugs defined as ‘comedications’ in this study. However, this study tries to 
control the effect of these comedications by including them as possible determinant of 
whether or not a patient might initiate either of the required drugs on the index date. 
3. There is no direct measure of severity of HF. If ignored this could lead to differential 
misclassification of exposure depending on the outcome. To compensate this, the 
study has used several other measures like count measures, CMS risk score etc. which 
may contribute in explaining some portion of severity. Added advantage of using 
these multiple measures is that severity is explored through different viewpoints 
including economic factors from past treatment cost and not just from clinical aspect. 
This could help to provide interesting insight into severity. Further, the systematic 
review by Ross et al., recommends including other important predictors like age and 
lab measures, which have been included in this study and which has strengthened the 
study.(Ross et al., 2008)  
4. The study has an inherent selection bias due to lack of randomly assigned treatment 
groups. This is accountable to the use of claims data. To confirm the findings the 
research question can be tested on different databases. 
5. Not all ACEI/ BBs are included in the MAPD data formulary. Only JNC standardized 
drugs have been identified from this data. New drugs are being explored each day, 
whose effect needs to be tested. However, a generic based definition of all the drugs 
as defined in standard guidelines makes it a good approach to identify the predictors 
of guideline recommended therapies. 
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6. The estimates from this study are not national level estimates. And additionally, as 
stated already the results are from the claims for a 1 year follow-up period. Thus, 
these results should be interpreted with caution. 
7. The study could not test the BBc2 category of the drug owing to their low sample 
size. Thus, future studies should focus on this group. 
8. There could be some missing variables like race which are not available in the data. 
However, considering many individual level characteristics have been captured in the 
analysis, the information related to these missing variables must have been captured. 
For example, Anderson recommends that race captures socio-economic status and 
genetic predisposition. This study captures socio-economic status by virtue of past 
cumulative cost and genetic predisposition by controlling all possible associated 
comorbidities and lab values. Despite that future studies should try to capture this 
information. 
Strength 
1. It provides information for ACEI/BB as monotherapy and as combination both and 
not just of monotherapy. It also includes a category of other therapies which is a 
group where these required drugs are not being prescribed but any other drug may or 
may not be prescribed. Thus, a multiple control ensures to eliminate any possible 
hidden bias. 
2. The sample frame includes patients with average age 70-75 years as existing in the 
community. Thus, the result of this study tries to explore the real world information 
and is not a controlled experiment of RCT which could have a biased population. 
3. The operational definition for drugs, required/not required/comedications in this study 
are not simply based on prescription date of a drug which could lead to 
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misclassification error of falsely classifying a patient as not taking a drug when infact 
he/she might have been prescribed the drug on some previous day to cover current 
day being observed. This study uses the information of days’ supply along with date 
of prescription to find the day level information of whether or not patient was 
prescribed a claim on that or on some day prior to the day being observed. This 
provides us much stronger and clearer operational definition of exposure in contrast to 
what is usually observed in other retrospective claims based studies.  
4. A further restrictive criteria of PDC <= 0.04 was used to exclude or include any 
patient from the washout period. This again tends to decrease a misclassification 
error. 
5. Use of Lab values including the observations with missing values minimizes 
confounding by indication. 
6. The study provides results across different BB classes. This is essential to know 
because clinicians often tend to replace 1 drug with other of same class to achieve 
therapeutic equivalent effect. 
7. The study provides evidence for all types of HF patients and not just those with Left-
ventricular EF (LVEF) <35% as chosen in CIBIS III trial.(R. Willenheimer et al., 
2004) As already stated, beta-PRESERVE trial is trying to target effect of using BBs 
in HFNEF patients too, our study provide some evidence with regard to those 
population and may support the need for the trial for all types of population for HF 
and thereafter, modification in guidelines.(Zhou et al., 2010) 
8. One of the important features of this study is that although the model controls for 
CMS risk score but additionally comorbidities as specified by CMS for HF patients 
from claims data have been controlled in this study.(S. M. Bernheim et al., 2010; 
41 
 
Susannah M. Bernheim et al., 2011) This helps to differentiate the probable reason for 
high CMS risk score instead of simply presenting the score. 
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Conclusion 
The results indicate that many patients were getting BBs as monotherapy especially BBc1. 
Being male is a significant predictor for initiating BBc3 and a high age is an important 
predictor for initiating BBC1. Different past severity measures seem to be high among 
patients initiating BBs indicating a possible association of BBs with severity.  Therefore, 
future studies need to explore the effect of an early initiation of BBs amongst HF patients. 
Finally, there is a need to regularly monitor the lab values especially BNP and also the 
history of comorbidities like Pneumonia, Trauma, mental disorders, acute myocardial 
infarction, chronic atherosclerosis and Rheumatic fever for these HF patients to decide 
whether or not to initiate on BBs and which class compared to ACEI. 
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Figure 1. Study design to explain inclusion/exclusion criteria of the cohort of elderly Heart Failure patients. 
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Figure 2. Flowchart to represent population included and excluded in the cohort 
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Table 1. Frequency Distribution of the treatment groups being compared 
trt_1 Frequency Percent 
Cohort 
Percent of overall HF Patient 
population 
ACEI 1194 18.57 11.59 
bbc1 - BBs 1519 23.62 14.74 
BBc3: Combined alpha and BBs 490 7.62 4.76 
Combined ACEI and BBc1 (ABC1) 257 4.00 2.49 
Combined ACEI and BBc3 (ABC3) 126 1.96 1.22 
Other Therapies 2844 44.23 27.61 
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Table 2. Mean Descriptive analysis for continuous variables, Mean±SD(Minimum-Maximum Range) 
SNo Label ACEI BBc1 BBc3 ABC1 ABC3 Others 
1 Age 
76.473±6.972,  
(65-99) 
77.33±6.956, 
(65-100) 
76.849±6.758, 
(65-99) 
75.872±7.066, 
(65-94) 
75.746±6.66, 
(65-91) 
77.386±7.592, 
(65-102) 
2 CMSRiskScore 
1.978±1.227,  
(0.277-9.804) 
1.976±1.266,  
(0.277-9.743) 
2.089±1.333,  
(0.304-8.464) 
1.806±1.151,  
(0.287-5.407) 
1.938±1.189,  
(0.277-5.429) 
1.691±1.234,  
(0.277-9.991) 
3 Count of hospitalization 
0.039±0.228, 
(0-3) 
0.028±0.172, 
(0-2) 
0.114±0.433, 
(0-4) 
0.035±0.184, 
(0-1) 
0.119±0.349, 
(0-2) 
0.034±0.209, 
(0-5) 
4 
Log of cumulative cost in 
washout pd. 
9.088±0.764,  
(6.282-11.737) 
9.113±0.783,  
(6.004-12.021) 
9.249±0.797,  
(5.978-11.524) 
9.074±0.733,  
(7.485-11.223) 
9.355±0.788,  
(7.502-11.111) 
9.043±1.092, 
(0-12.392) 
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Table 3. Population Characteristics of Cohort on the index Date 
# Table Characteristics Freq(Row%) 
1 Gender 
Female 3448,(53.64) 
Male 2980,(46.36) 
2 
R
eg
io
n
 
Others 409(6.361) 
Gulf Coast 5094,(79.222) 
SE Texas 927,(14.417) 
3 Plan type 
Healthy Advantage 5841,(90.84) 
Total Care/Others 589,(9.16) 
4 
C
o
m
o
rb
id
it
ie
s 
No Hypertension 2704,(42.053) 
Hypertension 3726,(57.947) 
5 
No Stroke 5038,(78.351) 
Stroke 1392,(21.649) 
6 
No CBVD 6315,(98.212) 
CBVD 115,(1.788) 
7 
No Renal Failure 4615,(71.773) 
Renal Failure 1815,(28.227) 
8 
No COPD 4474,(69.58) 
COPD 1956,(30.42) 
9 
No Pneumonia 5127,(79.736) 
Pneumonia 1303,(20.264) 
10 
No Diabetes 4390,(68.274) 
Diabetes 2040,(31.726) 
11 
C
o
m
o
rb
id
it
ie
s No Protein calorie malnutrition 6025,(93.701) 
Protein calorie malnutrition 405,(6.299) 
12 
No Dementia 5770,(89.736) 
Dementia 660,(10.264) 
13   
No Hemiplegia & Paralysis 5495,(85.459) 
  
Characteristics Freq(Row%) 
Hemiplegia & Paralysis 935,(14.541) 
14 
No Peripheral Vascular Disease 5145,(80.016) 
Peripheral Vascular Disease 1285,(19.984) 
15 
No Metastatic Cancer 6170,(95.956) 
Metastatic Cancer 260,(4.044) 
16 
No Trauma in last year 4666,(72.566) 
Trauma in last year 1764,(27.434) 
17 
No Mental disorder 5154,(80.156) 
Mental disorder 1276,(19.844) 
18 
No Liver Disease 6136,(95.428) 
Liver Disease 294,(4.572) 
19 
No CABG 6335,(98.523) 
CABG 95,(1.477) 
20 
No PTCA 5982,(93.033) 
PTCA 448,(6.967) 
21 
No unstable angina 6123,(95.226) 
Unstable Angina 307,(4.774) 
22 
C
o
m
o
rb
id
it
ie
s 
No anterior MI 6066,(94.339) 
Anterior MI 364,(5.661) 
23 
No other MI 4299,(66.858) 
Other MI 2131,(33.142) 
24 
No ACUTE MI 5817,(90.467) 
ACUTE MI 613,(9.533) 
25 
No chronic atherosclerosis 3991,(62.068) 
Chronic Atherosclerosis 2439,(37.932) 
26 
No cardiorespiratory disorder 5328,(82.862) 
Cardiorespiratory Disorder 1102,(17.138) 
27 No Rheumatic Fever 6188,(96.236) 
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Characteristics Freq(Row%) 
 Rheumatic fever 242,(3.764) 
28 
No Coronary Artery Disease 5768,(89.705) 
Coronary artery Disease 662,(10.295) 
29 
No Atrial fibrillation & flutter 5051,(78.554) 
Atrial fibrillation & flutter 1379,(21.446) 
30 Whf_hos 
No prior HF hos 6197,(96.376) 
Worsened HF hos 233,(3.624) 
31 
D
is
ea
se
 
S
ta
te
 Medicare/Medicaid Advantage 733,(11.4) 
Disabled/ESRD/Hospice/Institu
tion 191,(2.97) 
Other/Working Age 5506,(85.63) 
32 
B
N
P
 Normal: 0-99ng/L 105,(1.633) 
Elevated If, >99ng/L 153,(2.379) 
Missing Value 6172,(95.988) 
33 
B
U
N
 Normal: 8-23mg/dL 2041,(31.742) 
Abnormal 1370,(21.306) 
Missing Value 3019,(46.952) 
34 
L
D
L
 Optimal: <100mg/dL 1458,(22.675) 
Abnormal 941,(14.635) 
Missing Value 4031,(62.691) 
35 
H
b
*
 Normal* 1441,(22.411) 
Abnormal 1301,(20.233) 
Missing Value 3688,(57.356) 
36 N
a 
Normal: 135-145mmol/L 3158,(49.114) 
Abnormal 229,(3.561) 
Missing Value 3043,(47.325) 
37 LPO Flag 
No 1472,(22.914) 
Yes 4952,(77.086) 
  Characteristics Freq(Row%) 
38 P4QFlag 
No 5225,(81.336) 
Yes 1199,(18.664) 
39 Duration of HF <=0.25 yrs 2033,(31.617) 
0.25-1 yr 1634,(25.412) 
> 1 yrs 2763,(42.97) 
40 
Vasodilators 
No 5939,(92.364) 
Yes 491,(7.636) 
41 Calcium 
Channel 
Blockers 
No 5239,(81.477) 
Yes 1191,(18.523) 
42 
Diuretics 
No 4333,(67.387) 
Yes 2097,(32.613) 
43 Other 
Comedications 
No 4616,(71.788) 
Yes 1814,(28.212) 
 
 
*Hb: Normal: : 13.5-17.5g/dL for males and 12.0-15.5g/dL for 
female
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Table 4. Frequency distribution of Population characteristics across different treatment groups as initiated on the index Date. 
 
Table 
Characteristics 
ACE Inhibitor BBC1 BBc3 ABC1 ABC3 Other Therapies 
 
Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) 
1 Gender Female 647,(54.188) 867,(57.077) 227,(46.327) 140,(54.475) 45,(35.714) 1523,(53.495) 
Male 547,(45.812) 652,(42.923) 263,(53.673) 117,(45.525) 81,(64.286) 1324,(46.505) 
2 Region Others 62, 5.193) 86,(5.662) 22,(4.49) 8,(3.113) 7,(5.556) 226,(7.933) 
Gulf Coast 953,(79.816) 1223,(80.513) 394,(80.408) 206,(80.156) 96,(76.19) 2224,(78.062) 
SE Texas 179,(14.992) 210,(13.825) 74,(15.102) 43,(16.732) 23,(18.254) 399,(14.005) 
3 Plan 
type 
Healthy Advantage 1072,(89.782) 1368,(90.059) 445,(90.816) 233,(90.661) 116,(92.063) 2612,(91.681) 
Total Care/Others 122,(10.218) 151,(9.941) 45,(9.184) 24,(9.339) 10,(7.937) 237,(8.319) 
4 
C
o
m
o
rb
id
it
ie
s 
No Hypertension 529,(44.305) 639,(42.067) 174,(35.51) 111,(43.191) 46,(36.508) 1215,(42.647) 
Hypertension 665,(55.695) 880,(57.933) 316,(64.49) 146,(56.809) 80,(63.492) 1634,(57.353) 
5 No Stroke 957,(80.151) 1216,(80.053) 375,(76.531) 207,(80.545) 94,(74.603) 2195,(77.045) 
Stroke 237, (19.849) 303,(19.947) 115,(23.469) 50,(19.455) 32,(25.397) 654,(22.955) 
6 No CBVD 1173,(98.241) 1497,(98.552) 484,(98.776) 253,(98.444) 124,(98.413) 2789,(97.894) 
CBVD 21,(1.759) 22,(1.448) 6,(1.224) 4,(1.556) 2,(1.587) 60,(2.106) 
7 No Renal Failure 854,(71.524) 1091,(71.824) 306,(62.449) 184,(71.595) 84,(66.667) 2103,(73.815) 
Renal Failure 340,(28.476) 428,(28.176) 184,(37.551) 73,(28.405) 42,(33.333) 746,(26.185) 
8 No COPD 850,(71.189) 1079,(71.034) 337,(68.776) 184,(71.595) 83,(65.873) 1950,(68.445) 
COPD 344,(28.811) 440,(28.966) 153,(31.224) 73,(28.405) 43,(34.127) 899,(31.555) 
9 No Pneumonia 1009,(84.506) 1236,(81.369) 392,(80) 227,(88.327) 99,(78.571) 2174,(76.307) 
Pneumonia 185,(15.494) 283,(18.631) 98,(20) 30,(11.673) 27,(21.429) 675,(23.693) 
10 No Diabetes 796,(66.667) 1039,(68.4) 309,(63.061) 166,(64.591) 80,(63.492) 2008,(70.481) 
Diabetes 398,(33.333) 480,(31.6) 181,(36.939) 91,(35.409) 46,(36.508) 841,(29.519) 
11 No Protein calorie mal. 1141,(95.561) 1451,(95.523) 467,(95.306) 249,(96.887) 119,(94.444) 2604,(91.4) 
Protein calorie mal. 53,(4.439) 68,(4.477) 23,(4.694) 8,(3.113) 7,(5.556) 245,(8.6) 
12 No Dementia 1092,(91.457) 1396,(91.903) 438,(89.388) 241,(93.774) 112,(88.889) 2499,(87.715) 
Dementia 102,(8.543) 123,(8.097) 52,(10.612) 16,(6.226) 14,(11.111) 350,(12.285) 
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13  
Characteristics 
ACE Inhibitor BBC1 BBc3 ABC1 ABC3 Other Therapies 
 
Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) 
14 No Peripheral Vasc. Dis. 955,(79.983) 1208,(79.526) 372,(75.918) 206,(80.156) 98,(77.778) 2315,(81.257) 
Peripheral Vasc. Dis. 239,(20.017) 311,(20.474) 118,(24.082) 51,(19.844) 28,(22.222) 534,(18.743) 
15 
C
o
m
o
rb
id
it
ie
s 
No Metastatic Cancer 1168,(97.822) 1473,(96.972) 479,(97.755) 254,(98.833) 124,(98.413) 2677,(93.963) 
Metastatic Cancer 26,(2.178) 46,(3.028) 11,(2.245) 3,(1.167) 2,(1.587) 172,(6.037) 
16 No Trauma in last year 878,(73.534) 1156,(76.103) 359,(73.265) 190,(73.93) 92,(73.016) 1999,(70.165) 
Trauma in last year 316,(26.466) 363,(23.897) 131,(26.735) 67,(26.07) 34,(26.984) 850,(29.835) 
17 No Mental disorder 981,(82.161) 1234,(81.238) 394,(80.408) 198,(77.043) 103,(81.746) 2251,(79.01) 
Mental disorder 213,(17.839) 285,(18.762) 96,(19.592) 59,(22.957) 23,(18.254) 598,(20.99) 
18 No Liver Disease 1148,(96.147) 1442,(94.931) 473,(96.531) 248,(96.498) 123,(97.619) 2708,(95.051) 
Liver Disease 46,(3.853) 77,(5.069) 17,(3.469) 9,(3.502) 3,(2.381) 141,(4.949) 
19 No CABG 1180,(98.827) 1494,(98.354) 480,(97.959) 252,(98.054) 122,(96.825) 2812,(98.701) 
CABG 14,(1.173) 25,(1.646) 10,(2.041) 5,(1.946) 4,(3.175) 37,(1.299) 
20 No PTCA 1108,(92.797) 1410,(92.824) 445,(90.816) 225, 87.549) 104,(82.54) 2696,(94.63) 
PTCA 86,(7.203) 109,(7.176) 45,(9.184) 32,(12.451) 22,(17.46) 153,(5.37) 
21 No unstable angina 1133,(94.891) 1440,(94.799) 464,(94.694) 234,(91.051) 117,(92.857) 2742,(96.244) 
Unstable Angina 61,(5.109) 79,(5.201) 26,(5.306) 23,(8.949) 9,(7.143) 107,(3.756) 
22 No anterior MI 1112,(93.132) 1425,(93.812) 455,(92.857) 240,(93.385) 109,(86.508) 2731,(95.858) 
Anterior MI 82,(6.868) 94,(6.188) 35,(7.143) 17,(6.615) 17,(13.492) 118,(4.142) 
23 No other MI 848,(71.022) 1003,(66.03) 314,(64.082) 169,(65.759) 73,(57.937) 1902,(66.76) 
Other MI 346,(28.978) 516,(33.97) 176,(35.918) 88,(34.241) 53,(42.063) 947,(33.24) 
24 No ACUTE MI 1089,(91.206) 1388,(91.376) 429,(87.551) 219,(85.214) 103,(81.746) 2596,(91.12) 
ACUTE MI 105,(8.794) 131,(8.624) 61,(12.449) 38,(14.786) 23,(18.254) 253,(8.88) 
25 No chronic atherosclerosis 758,(63.484) 934,(61.488) 241,(49.184) 154,(59.922) 56,(44.444) 1860,(65.286) 
Chronic Atherosclerosis 436,(36.516) 585,(38.512) 249,(50.816) 103,(40.078) 70,(55.556) 989,(34.714) 
 
26 
No Cardiorespiratory 
disorder 1036,(86.767) 1312,(86.373) 404,(82.449) 221,(85.992) 103,(81.746) 2260,(79.326) 
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Characteristics ACE Inhibitor BBC1 BBc3 ABC1 ABC3 Other Therapies 
 Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) 
Cardiorespiratory 
Disorder 158,(13.233) 207,(13.627) 86,(17.551) 36,(14.008) 23,(18.254) 589,(20.674) 
27 No Rheumatic Fever 1156,(96.817) 1454,(95.721) 467,(95.306) 244,(94.942) 113,(89.683) 2760,(96.876) 
Rheumatic fever 38,(3.183) 65,(4.279) 23,(4.694) 13,(5.058) 13,(10.317) 89,(3.124) 
28 No Coronary Artery 
Disease 1068,(89.447) 1350,(88.874) 432,(88.163) 218,(84.825) 108,(85.714) 2599,(91.225) 
Coronary artery Disease 126,(10.553) 169,(11.126) 58,(11.837) 39,(15.175) 18,(14.286) 250,(8.775) 
29 No Atrial fibrillation & 
flutter 974,(81.575) 1162,(76.498) 367,(74.898) 202,(78.599) 92,(73.016) 2265,(79.502) 
Atrial fibrillation & flutter 220,(18.425) 357,(23.502) 123,(25.102) 55,(21.401) 34,(26.984) 584,(20.498) 
30 Whf 
hos 
No prior HF 
hospitalization 1156,(96.817) 1479,(97.367) 448,(91.429) 248,(96.498) 112,(88.889) 2760,(96.876) 
Worsened HF 
hospitalization 38,(3.183) 40,(2.633) 42,(8.571) 9,(3.502) 14,(11.111) 89,(3.124) 
31 
D
S
 
Medicare/Medicaid Ad. 152,(12.73) 177,(11.652) 54,(11.02) 26,(10.117) 11,(8.73) 313,(10.986) 
Disabled/ESRD/Hospice/I
nstit. 29,(2.429) 40,(2.633) 14,(2.857) 5,(1.946) 3,(2.381) 101,(3.545) 
Other/Working Age 1013,(84.841) 1302,(85.714) 422,(86.122) 226,(87.938) 112,(88.889) 2435,(85.469) 
32 
B
N
P
 Normal: 0-99ng/L 30,(2.513) 18,(1.185) 10,(2.041) 2,(0.778) 2,(1.587) 43,(1.509) 
Elevated If, >99ng/L 29,(2.429) 36,(2.37) 29,(5.918) 7,(2.724) 6,(4.762) 46,(1.615) 
Missing Value 1135,(95.05) 1465,(96.445) 451,(92.041) 248,(96.498) 118,(93.65) 2760,(96.876) 
33 
B
U
N
 Normal: 8-23mg/dL 420,(35.176) 483,(31.797) 163,(33.265) 79,(30.739) 36,(28.571) 857,(30.081) 
Abnormal 282,(23.618) 365,(24.029) 148,(30.204) 60,(23.346) 34,(26.984) 481,(16.883) 
Missing Value 492,(41.206) 671,(44.174) 179,(36.531) 118,(45.914) 56,(44.444) 1511,(53.036) 
34 
L
D
L
 Optimal: <100mg/dL 341,(28.559) 380,(25.016) 151,(30.816) 68,(26.459) 36,(28.571) 480,(16.848) 
Abnormal 169,(14.154) 237,(15.602) 72,(14.694) 38,(14.786) 19,(15.079) 407,(14.286) 
Missing Value 684,(57.286) 902,(59.381) 267,(54.49) 151,(58.755) 71,(56.349) 1962,(68.866) 
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35 
H
b
 
Characteristics ACE Inhibitor BBC1 BBc3 ABC1 ABC3 Other Therapies 
 Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) Freq(Row%) 
Normal* 294,(24.623) 377,(24.819) 106,(21.633) 63,(24.514) 22,(17.46) 577,(20.253) 
Abnormal 268,(22.446) 309,(20.342) 145,(29.592) 48,(18.677) 33,(26.19) 498,(17.48) 
Missing Value 632,(52.931) 833,(54.839) 239,(48.776) 146,(56.809) 71,(56.349) 1774,(62.267) 
36 
N
a 
Normal: 135-145mmol/L 660,(55.276) 793,(52.205) 290,(59.184) 133,(51.751) 66,(52.381) 1213,(42.576) 
Abnormal 40,(3.35) 47,(3.094) 21,(4.286) 6,(2.335) 3,(2.381) 112,(3.931) 
Missing Value 494,(41.374) 679,(44.7) 179,(36.531) 118,(45.914) 57,(45.238) 1524,(53.492) 
37 LPO No 252,(21.106) 336,(22.12) 93,(18.98) 60,(23.346) 24,(19.048) 711,(25.009) 
Yes 942,(78.894) 1183,(77.88) 397,(81.02) 197,(76.654) 102,(80.95) 2132,(74.991) 
38 P4QFlag No 929,(77.806) 1203,(79.197) 379,(77.347) 212,(82.49) 96,(76.19) 2410,(84.77) 
Yes 265,(22.194) 316,(20.803) 111,(22.653) 45,(17.51) 30,(23.81) 433,(15.23) 
39 Duration 
of HF 
Duration of HF ≤0.25 yrs 162,(13.568) 222,(14.615) 76,(15.51) 52,(20.233) 26,(20.635) 1495,(52.56) 
Duration of HF 0.25-1 yr 342,(8.643) 461,(30.349) 155,(31.633) 77,(29.961) 33,(26.19) 566,(19.902) 
Duration of HF > 1 yrs 690,(57.789) 836,(55.036) 259,(52.857) 128,(49.805) 67,(53.175) 783,(27.532) 
40 Vasodila
tors 
No 1093,(91.54) 1352,(89.006) 418,(85.306) 225,(87.549) 106,(84.12) 2745,(96.519) 
Yes 101,(8.459) 167,(10.994) 72,(14.694) 32,(12.451) 20,(15.873) 99,(3.481) 
41 
Ca 
Channel 
Blockers 
No 916,(76.717) 1161,(76.432) 400,(81.633) 198,(77.043) 112,(88.88) 2452,(86.217) 
Yes 278,(23.283) 358,(23.568) 90,(18.367) 59,(22.957) 14,(11.111) 392,(13.783) 
42 Diuretic
s 
No 719,(60.218) 906,(59.645) 261,(53.265) 132,(51.362) 49,(38.889) 2266,(79.677) 
Yes 475,(39.782) 613,(40.355) 229,(46.735) 125,(48.638) 77,(61.111) 578,(20.323) 
43 Other 
Comedi
cations 
No 860,(72.027) 1108,(72.943) 0,(0) 182,(70.817) 0,(0) 2466,(86.709) 
Yes 334,(27.973) 411,(27.057) 490,(100) 75,(29.183) 126,(100) 378,(13.291) 
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Table 5. ODDS RATIOS for Treatment Initiation on the index date 
Effect BBc1 BBc3 ABC1 ABC3 Other Therapy 
OR (Conf. Int.) OR (Conf. Int.) OR (Conf. Int.) OR (Conf. Int.) OR (Conf. Int.) 
Gender Male vs Female 0.894 
(0.762 - 1.051) 
1.293 
(1.034 - 1.617) 
1.008 
(0.758 - 1.341) 
1.817 
(1.213 - 2.721) 
1.019 
(0.872 - 1.191) 
Region Gulf Coast vs Others 0.948 
(0.64 - 1.404) 
0.977 
(0.548 - 1.742) 
1.971 
(0.861 - 4.516) 
0.545 
(0.211 - 1.407) 
0.751 
(0.519 - 1.087) 
SE Texas   vs Others 0.856 
(0.572 - 1.28) 
1.048 
(0.582 - 1.887) 
1.913 
(0.829 - 4.418) 
0.831 
(0.318 - 2.173) 
0.612 
(0.419 - 0.893) 
Plan 
type 
Healthy Advantage vs Total Care/Plus 
plan/Optimacare/Others/Missing Value 
0.948 
(0.71 - 1.266) 
1.058 
(0.701 - 1.597) 
0.95 
(0.564 - 1.601) 
1.282 
(0.6 - 2.738) 
1.245 
(0.934 - 1.659) 
C
o
m
o
rb
id
it
ie
s 
Hypertension vs No Hypertension 1.109 
(0.872 - 1.41) 
1.173 
(0.835 - 1.648) 
0.806 
(0.519 - 1.253) 
0.797 
(0.434 - 1.466) 
0.819 
(0.651 - 1.031) 
Stroke vs No Stroke 0.934 
(0.681 - 1.281) 
1.12 
(0.747 - 1.678) 
0.796 
(0.448 - 1.416) 
0.952 
(0.474 - 1.912) 
0.997 
(0.733 - 1.356) 
CBVD vs No CBVD 0.827 
(0.442 - 1.549) 
0.701 
(0.272 - 1.804) 
0.814 
(0.264 - 2.511) 
0.757 
(0.164 - 3.499) 
0.795 
(0.451 - 1.404) 
Renal Failure vs No Renal Failure 0.921 
(0.743 - 1.143) 
1.195 
(0.895 - 1.595) 
0.969 
(0.66 - 1.424) 
0.853 
(0.511 - 1.422) 
0.815 
(0.661 - 1.005) 
COPD vs No COPD 0.919 
(0.746 - 1.132) 
0.817 
(0.615 - 1.086) 
0.936 
(0.647 - 1.354) 
0.885 
(0.538 - 1.456) 
1.077 
(0.88 - 1.317) 
Pneumonia vs No Pneumonia 1.321 
(1.028 - 1.698) 
1.05 
(0.751 - 1.467) 
0.627 
(0.385 - 1.022) 
1.064 
(0.602 - 1.88) 
1.426 
(1.121 - 1.814) 
Diabetes vs No Diabetes 0.887 
(0.724 - 1.087) 
0.848 
(0.644 - 1.117) 
1.123 
(0.782 - 1.613) 
0.825 
(0.511 - 1.331) 
0.884 
(0.725 - 1.078) 
Protein calorie malnutrition vs No 
Protein calorie malnutrition 
0.894 
(0.598 - 1.339) 
0.858 
(0.494 - 1.493) 
0.737 
(0.327 - 1.663) 
0.852 
(0.333 - 2.177) 
1.337 
(0.93 - 1.923) 
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Dementia vs No Dementia 0.874 
(0.642 - 1.189) 
1.142 
(0.765 - 1.705) 
0.635 
(0.349 - 1.158) 
1.4 
(0.709 - 2.765) 
1.131 
(0.85 - 1.506) 
Hemiplegia and Paralysis vs No 
Hemiplegia and Paralysis 
1.056 
(0.741 - 1.504) 
0.812 
(0.511 - 1.29) 
1.184 
(0.624 - 2.248) 
1.054 
(0.48 - 2.315) 
1.226 
(0.871 - 1.727) 
Peripheral Vascular Disease vs No 
Peripheral Vascular Disease 
0.999 
(0.79 - 1.263) 
0.898 
(0.66 - 1.224) 
0.909 
(0.599 - 1.379) 
0.681 
(0.396 - 1.171) 
0.869 
(0.691 - 1.094) 
Metastatic Cancer vs No Metastatic 
Cancer 
1.416 
(0.849 - 2.361) 
0.967 
(0.459 - 2.036) 
0.623 
(0.182 - 2.13) 
0.766 
(0.171 - 3.434) 
2.665 
(1.674 - 4.243) 
Trauma in last year vs No Trauma in 
last year 
0.74 
(0.598 - 0.917) 
0.756 
(0.566 - 1.01) 
0.944 
(0.647 - 1.378) 
0.737 
(0.442 - 1.228) 
1.116 
(0.909 - 1.37) 
Mental disorder vs No Mental disorder 1.085 
(0.855 - 1.376) 
1.038 
(0.753 - 1.43) 
1.533 
(1.022 - 2.3) 
0.866 
(0.492 - 1.525) 
1.005 
(0.8 - 1.263) 
Liver Disease vs No Liver Disease 1.353 
(0.914 - 2.004) 
0.732 
(0.405 - 1.323) 
0.789 
(0.368 - 1.692) 
0.484 
(0.142 - 1.651) 
1.092 
(0.738 - 1.614) 
CABG vs No CABG 1.53 
(0.73 - 3.205) 
1.282 
(0.503 - 3.268) 
0.841 
(0.265 - 2.669) 
0.912 
(0.248 - 3.351) 
1.224(0.584 - 
2.565) 
PTCA vs No PTCA 0.933 
(0.646 - 1.348) 
0.967 
(0.601 - 1.555) 
1.279 
(0.728 - 2.247) 
1.581 
(0.789 - 3.168) 
0.688 
(0.475 - 0.997) 
Unstable Angina vs No unstable angina 0.95 
(0.644 - 1.402) 
0.83 
(0.491 - 1.403) 
1.346 
(0.748 - 2.425) 
0.667 
(0.289 - 1.541) 
0.761 
(0.514 - 1.128) 
Anterior MI vs No anterior MI 0.87 
(0.619 - 1.223) 
0.808 
(0.514 - 1.269) 
0.664 
(0.361 - 1.22) 
1.327 
(0.687 - 2.564) 
0.686 
(0.485 - 0.971) 
Other MI vs No other MI 1.09 
(0.82 - 1.45) 
0.806 
(0.544 - 1.192) 
1.241 
(0.761 - 2.024) 
1.128 
(0.594 - 2.141) 
1.211 
(0.924 - 1.588) 
ACUTE MYOCARDIAL 
INFARCTION vs No ACUTE MI 
0.87 
(0.638 - 1.187) 
1.026 
(0.694 - 1.517) 
1.798 
(1.103 - 2.928) 
1.192 
(0.639 - 2.222) 
0.791 
(0.586 - 1.068) 
Chronic Atherosclerosis vs No chronic 
atherosclerosis 
1.087 
(0.862 - 1.372) 
1.69 
(1.231 - 2.321) 
0.998 
(0.654 - 1.522) 
1.944 
(1.088 - 3.473) 
1.074 
(0.858 - 1.345) 
Cardiorespiratory Failure and shock vs 0.895 0.966 1.076 0.793 1.61 
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No cardiorespiratory failure and shock (0.681 - 1.177) (0.677 - 1.38) (0.663 - 1.746) (0.427 - 1.474) (1.246 - 2.082) 
Rheumatic fever vs No Rheumatic 
Fever 
1.214 
(0.788 - 1.869) 
1.043 
(0.591 - 1.84) 
1.341 
(0.669 - 2.691) 
2.224 
(1.049 - 4.712) 
0.822 
(0.53 - 1.274) 
Coronary artery disease vs No 
Coronary Artery disease 
1.042 
(0.782 - 1.389) 
0.833 
(0.567 - 1.224) 
1.198 
(0.747 - 1.919) 
0.802 
(0.424 - 1.517) 
1.099 
(0.825 - 1.463) 
Atrial fibrillation and flutter vs No 
Atrial fibrillation and flutter 
1.33 
(0.991 - 1.786) 
1.388 
(0.928 - 2.075) 
1.082 
(0.656 - 1.783) 
1.132 
(0.598 - 2.141) 
0.955 
(0.718 - 1.269) 
whf_hos       YES vs NO 0.691 
(0.43 - 1.111) 
2.196(1.342 - 
3.593) 
0.895 
(0.407 - 1.971) 
2.568 
(1.233 - 5.351) 
0.757 
(0.485 - 1.182) 
Disease 
State 
Disabled/ESRD/Hospice/Institutional vs 
Medi/Medi 
1.322 
(0.728 - 2.402) 
0.985 
(0.433 - 2.241) 
1.054 
(0.339 - 3.281) 
0.993 
(0.225 - 4.382) 
2.342 
(1.336 - 4.104) 
Other/Working Age  vs Medi/Medi 1.15 
(0.884 - 1.497) 
1.136 
(0.781 - 1.652) 
1.262 
(0.769 - 2.07) 
1.237 
(0.61 - 2.507) 
1.084 
(0.841 - 1.396) 
Age 1.018 
(1.006 - 1.03) 
1.006 
(0.99 - 1.023) 
0.996 
(0.976 - 1.017) 
0.985 
(0.956 - 1.015) 
1.02 
(1.009 - 1.032) 
cmssqrt 0.977 
(0.563 - 1.697) 
0.881 
(0.413 - 1.88) 
0.655 
(0.247 - 1.74) 
0.379 
(0.105 - 1.366) 
1.628 
(0.964 - 2.752) 
Duratio
n of HF 
0.25-1 yr. vs <=0.25 yrs. 0.974 
(0.753 - 1.261) 
1.024 
(0.722 - 1.454) 
0.729 
(0.478 - 1.111) 
0.631 
(0.352 - 1.13) 
0.151 
(0.12 - 0.189) 
> 1 yrs.   vs <=0.25 yrs. 0.875 
(0.683 - 1.122) 
0.837 
(0.595 - 1.178) 
0.619 
(0.411 - 0.931) 
0.688 
(0.394 - 1.2) 
0.1 
(0.08 - 0.125) 
Log of cumulative cost 1.013 
(0.881 - 1.164) 
1.121 
(0.922 - 1.363) 
1.003 
(0.784 - 1.284) 
1.554 
(1.118 - 2.158) 
0.772 
(0.678 - 0.878) 
 Vasodilators YES vs NO 1.382 
(1.055 - 1.811) 
1.625 
(1.156 - 2.284) 
1.424 
(0.915 - 2.215) 
1.718(0.985 - 
2.997) 
0.526 
(0.384 - 0.72) 
 Calcium Channel Blockers       YES vs NO 0.982 
(0.816 - 1.18) 
0.719 
(0.546 - 0.946) 
0.945 
(0.68 - 1.314) 
0.402 
(0.223 - 0.725) 
0.582 
(0.481 - 0.705) 
 Diuretics  YES vs NO 1.033 
(0.88 - 1.212) 
1.293 
(1.037 - 1.613) 
1.467 
(1.108 - 1.943) 
2.675 
(1.802 - 3.971) 
0.484 
(0.411 - 0.57) 
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 BNP Elevated value, >99ng/L vs 
Normal: 0-99ng/L 
1.89 
(0.875 - 4.085) 
2.131 
(0.864 - 5.255) 
3.55 
(0.666 - 18.911) 
2.026 
(0.358 - 11.467) 
0.978 
(0.466 - 2.056) 
 Missing Value           vs Normal: 
0-99ng/L 
1.982 
(1.089 - 3.607) 
1.147 
(0.547 - 2.404) 
3.302 
(0.768 - 14.198) 
1.368 
(0.308 - 6.074) 
1.491 
(0.867 - 2.566) 
 BUN Abnormal      vs Normal: 8-
23mg/dL 
1.174 
(0.945 - 1.458) 
1.172 
(0.876 - 1.567) 
1.195 
(0.807 - 1.769) 
1.324 
(0.776 - 2.258) 
1.092 
(0.877 - 1.358) 
 Missing Value vs Normal: 8-
23mg/dL 
0.522 
(0.159 - 1.714) 
1.627 
(0.254 - 10.4) 
1.581 
(0.116 - 21.62) 
0.282 
(0.029 - 2.755) 
0.784 
(0.244 - 2.52) 
 LDL Abnormal      vs Optimal: 
<100mg/dL 
1.231 
(0.959 - 1.58) 
1.017 
(0.721 - 1.435) 
1.11 
(0.71 - 1.734) 
1.134 
(0.616 - 2.087) 
1.56 
(1.214 - 2.006) 
 Missing Value vs Optimal: 
<100mg/dL 
1.026 
(0.81 - 1.3) 
0.959 
(0.699 - 1.315) 
0.98 
(0.636 - 1.511) 
0.752 
(0.415 - 1.363) 
1.616 
(1.276 - 2.046) 
 Hb Abnormal      vs Normal: 13.5-
17.5g/dL for males and 12.0-
15.5g/dL for females 
0.874 
(0.688 - 1.109) 
1.189 
(0.86 - 1.643) 
0.822 
(0.53 - 1.274) 
1.199 
(0.651 - 2.21) 
0.969 
(0.763 - 1.23) 
 Missing Value vs Normal: 13.5-
17.5g/dL for males and 12.0-
15.5g/dL for females 
0.942 
(0.73 - 1.215) 
1.15 
(0.804 - 1.645) 
0.946 
(0.599 - 1.495) 
1.402 
(0.727 - 2.703) 
1.048 
(0.813 - 1.351) 
 Na Abnormal      vs Normal: 135-
145mmol/L 
0.927 
(0.596 - 1.44) 
1.044 
(0.597 - 1.828) 
0.657 
(0.269 - 1.606) 
0.529 
(0.153 - 1.823) 
1.331 
(0.876 - 2.02) 
 Missing Value vs Normal: 135-
145mmol/L 
2.358 
(0.713 - 7.796) 
0.583 
(0.091 - 3.737) 
0.801 
(0.059 - 10.91) 
5.34 
(0.538 - 52.976) 
1.579 
(0.489 - 5.101) 
LPOFlag       Y vs N 0.989 
(0.774 - 1.262) 
1.055 
(0.743 - 1.498) 
0.957 
(0.63 - 1.453) 
1.683 
(0.918 - 3.089) 
1.135 
(0.898 - 1.436) 
P4QFlag       Y vs N 0.902 
(0.746 - 1.092) 
0.973 
(0.748 - 1.264) 
0.733 
(0.512 - 1.051) 
0.978 
 
(0.622 - 1.539) 
0.52 
(0.428 - 0.632) 
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Manuscript #2 
Risk of First subsequent Hospitalization among Elderly Heart Failure Patients 
initiating Angiotensin-Converting Enzyme Inhibitors (ACEI) vs. Beta-Blockers(BBs) - a 
comparative effectiveness analysis 
 
 
Finding: The results indicate a statistically non-significant effect of BBc1 and BBc3 in 
comparison to ACEI on first subsequent HF hospitalization. 
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Abstract 
Objective: To estimate the effect of initiating Beta-Blockers(BBs) vs. Angiotensin-
Converting Enzyme Inhibitors(ACEIs) among elderly Heart Failure(HF) patients on risk of 
first subsequent HF hospitalization. 
Methods: Using elderly(age≥65 years) HF patients initiating ACEI or a category 1 
BB(BBc1) and category 3 BB(BBc3 i.e. BBs with combined alpha and beta blocking 
activity), were identified from Medicare Advantage Prescription Drug Plan for 2008-2011. 
The survival probabilities of first subsequent hospitalization were obtained by inverse 
probability weighted count process model for a follow-up of a year using SAS 9.3 at the p-
value of 0.05. 
Results: There were 248 (3.86%) first subsequent hospitalizations in the cohort of 6430 
elderly HF patients with 18176 person-interval observations. The hazard ratio for first 
subsequent hospitalizations were 0.562(95%CI:0.28- 1.13) and 1.242(95%CI:0.64- 2.43) 
respectively for BBc1 and BBc3 as initiation therapies with respect to ACEI. 
Conclusions:  The results indicate a statistically non-significant effect of BBc1 and BBc3 
in comparison to ACEI on first subsequent HF hospitalization. 
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Introduction 
Heart Failure (HF) imposes a major health and economic burdens. As per 2009 report, in 
US there were more than 5.5 million adults with HF of which 10 per 1000 were over 65 years 
of age.(Shafazand et al., 2010) That year the disease led to an estimated direct and indirect 
cost of 37.2 billion. American College of Cardiology and the American Heart Association 
(ACC/AHA) 2005 guidelines recommend angiotensin-converting enzyme inhibitor (ACEI) or 
angiotensin receptor blocker (ARB) for stage A HF (mild HF or patients at risk of HF) patient 
and also for patients having vascular disease or diabetes.(Shafazand et al., 2010) These 
guidelines also recommend addition of Beta-Blockers (BB) for stage B HF (i.e. mild to 
moderate HF) patients. And for patient with mild to severe Stage C HF, additional drug 
therapies may include diuretics or digitalis or combination therapies with hydralazine and 
nitrates. Therefore, as per these guideline recommendations, BB is for stage B HF patients as 
an add-on therapy after ACEI/ARB.  
One of possible reasons for preferring ACEI over BBs is initiation of clinical trials for 
ACEI much before BBs trials.(Chonchol et al., 2008; de Boer & van Veldhuisen, 2008; 
Remme, 2007, 2008; Remme et al., 2004) The majority of trials were conducted to compare 
ACEI over placebos. The ample of evidence generated in favor of ACEI against placebo 
made it almost unethical standard to conduct a HF trial without prescribing ACEI as the 
standard therapy. Even when BB trials were conducted ACEI was part of approximately 90% 
of the trial’s patient population.(Flather et al., 2005; Remme, 2008) This makes it hard to 
attribute the protective effect of the trial solely to beta-blockade and thus demands to bring 
evidence from alternative research strategies like observational studies before planning for 
RCTs.  
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The existing past literature, suggests that BBs play an important role in reducing the risk 
of Sudden Cardiac Death (SCD) and ischemia compared to ACEI.(Remme, 2007) It is also 
easier to achieve a higher dose of BB and an early inhibition of cardiac remodeling by rapid 
activation of sympathetic and renin angiotensin system(RAS) compared to when ACEI is 
administered first. (Remme, 2007, 2008) The increased RAS activation by BBs was also 
justified in SOLVD trial on grounds of increased Na and water retention and thus this pre-
treatment with BB was reported to diminish increased serum creatinine level following 
ACEI.(Knight et al., 1999) These past literature enforce us to believe in the plausible 
protective effect of BBs, as mentioned earlier, compared to ACEI. And it seems reasonable to 
hypothesize that BBs are more beneficial for elderly HF patients in comparison to ACEI.  
Evidence from Randomized Clinical Trial (RCTs) 
There is  evidence from various RCTs that support the abovementioned hypothesis. Sliwa 
et al demonstrated significant improvement in Left Ventricular Ejection Fraction (LVEF) and 
reduction in NT-proBNP, a biomarker for HF progression, in New York Heart association 
functional Class (NYHA) II-III HF and patients with idiopathic dilated cardiomyopathy for 
carvedilol (BB) patients compared to perindopril (ACEI) group.(Sliwa et al., 2004) Both 
drugs were equally well tolerated.  Along with established benefits of cardiac remodeling via 
BBs, the CARMEN trial also compared the combination therapy to monotherapy of ACEI 
and BBs and concluded that addition of BBs to ACEI therapy is a superior therapy to either 
monotherapy.(Komajda et al., 2004; Remme, 2007, 2008) The trial found more 
cardiovascular hospitalization in the enalapril group but found comparable tolerability in 
terms of adverse events and withdrawal rate for ACEI and BB groups.(Komajda et al., 2004; 
Remme et al., 2004) Even CIBIS III trial confirmed Bisoprolol to be a safe and efficacious 
drug compared to enalapril with non-significant differences in all clinical outcomes studied in 
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the trial. The trial reported similar all-cause mortality, all-cause hospitalization, and 
cardiovascular hospitalization, tolerability in both groups and worsening of CHF requiring 
continued hospitalization while in hospital.(R. Willenheimer, 2009) At the end of the study 
period, despite more discontinuation in ACEI group, comparable numbers of patients were 
retained in the trial who had improved 1 or more NYHA class. Despite a non-significantly 
higher risk of worsening Heart Failure (WHF) related hospitalization or cases while in 
hospital for the bisoprolol group, the trial demonstrated tendency towards less sudden death 
with bisoprolol group (8 versus 16 patients in the enalapril group, HR 0.50; 95% CI 0.21–
1.16, p=0.11).(Remme, 2008; R. Willenheimer et al., 2005) The CIBIS III trial has been an 
important trial in this direction. Because the sample frame of this trial focused on the elderly 
population it is considered to have provided some important observations for this population. 
It states that enhanced sympathetic activation with age may lead to myocardial infarction 
(MI) or arrhythmias. However, an early start on the BBs can be used to control accelerated 
sympathetic responses which could otherwise lead to ischemia or arrhythmias, thereby  
suggesting the utility of BBs among elderly population as well.(R. Willenheimer et al., 2005) 
The trial therefore provided more evidence to support SENIOR trial which observed that the 
BBs are well tolerated among elderly population.(Flather et al., 2005)   
The utility of BBs(metoprolol succinate)  across various clinical outcomes is also being 
tested for HF with normal left ventricular ejection fraction (HFNEF) in a multicenter trial, the 
beta-PRESERVE trial.(Morrissey et al., 2011; Zhou et al., 2010) This study  justified the 
need for long-term RCT on the basis of few prospective, few observational and subgroups 
analysis of RCTs that past literature reveals beneficial effect of BBs even in HFNEF patients 
for whom there is a lack of any specific therapy.(Zhou et al., 2010)  This implies that the 
preference of the BBs or testing of their preference over ACEI should not be limited to HF 
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patients with depressed LVEF only. Rather, it should be extended to the patients with HFNEF 
as well. This means, a HF patient, irrespective of his or her Ejection fraction (EF)  can be 
hypothesized to benefit from BBs compared to or at least for their equivalence to ACEI. 
So, where do RCTs lack? 
As reported previously, despite comparable clinical outcomes of bisoprolol with enalapril 
group in CIBIS III trial, more WHF related hospitalization or cases were reported for the 
bisoprolol group while in hospital.(R. Willenheimer et al., 2005) Studies have also reported 
that the effect of BBs varies with the type of BB under scrutiny. For example, COMET trial 
showed greater reduction in fatal and non-fatal MIs and SCD due to carvedilol treatment 
compared to metoprolol treatment (Beta-1 selective agent). Bisoprolol has a similar profile as 
of metoprolol. This may imply that the type of BB is an important factor in revealing  the 
most effective BBs of all or for comparing these BBs with another class of drugs like ACEI 
in this case. This raises a question if it is possible to change the results of CIBIS III trial with 
the replacement of bisoprolol (Beta-1 selective drug) with a non-selective BB for e.g. 
carvedilol.(Poole-Wilson et al., 2003) Although we would like to conduct an RCT, but 
considering these existing gaps in research, its cost, time and other practical limitations, it is 
difficult to compare all or even more than 2-3 BBs with another anti-hypertensive class in a 
single trial. This makes RCTs as an infeasible design approach to answer the aforementioned 
or similar comparative effectiveness studies that require class comparisons.  
There are other limitations of RCTs too, due to which there is a need of some alternative 
approaches. For example, in SENIORS trial for 90% of the patients in the sample frame, BB 
was given along with ACEI. So, it was difficult to conclude if the protective effect as 
observed in the BB group was solely due to BB.(Flather et al., 2005) Not just SENIOR trial, 
but almost all clinical trials consider it unethical to conduct a clinical trial among HF patients 
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without prescribing ACEI, thereby discarding the RCT as a good design for the 
purpose.(Remme, 2007, 2008)  
Apart from that the age of patients included in these clinical trials makes it difficult to 
generalize the results to elderly HF patients as prevailing in community. In CARMEN trial, 
on average, Patients were 10 years younger than the average age of HF patients in community 
(73-75 years of age).(Jafar et al., 2003) And as stated earlier, ageing is an important factor 
that correlates with increased nor-epinephrine plasma spillover and an increase in end 
diastolic volume.(Remme et al., 2004) It, therefore, makes it difficult to generalize the results 
of CARMEN trial to elderly HF population of the community. And the trials which include 
elderly patients include comparatively healthy volunteers, thereby providing results on biased 
populations.(Richardson et al., 2010) One of the major trials for this population, the CIBIS III 
trial, does not address the safety and efficacy of BB for elderly patients’ clinical end-points. 
This trial used up most of the time for initiation and up-titration of bisoprolol, so despite 
WHF being the phenomenon of  BB introduction, the trial was not a good setting to answer if 
BB can be used as a first-line therapy especially for elderlies. This study population could not 
gain optimal clinical effects of full and prolonged BB, such as reduction in death and SCD. 
The positive effects of BB need some time to become evident.(R. Willenheimer et al., 2005)  
Evidence from the observational Studies 
Although, none of the existing observational studies have compared ACEI vs different 
categories of BB and their combinations (ACEI+BB) in elderly HF patients for the risk of 
WHF, a few interpretations are worth noting. An article by Richardson et al, compares 
combination of ACEI/ARB and BB as essential cardiac drugs which should be prescribed to 
all elderly HF patients.(Richardson et al., 2010) This study concluded that mortality rates are 
significantly lower for those receiving ACEI/ARB alone (OR 0.24, 0.11-0.50), BBs alone 
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(OR 0.17, 0.07-0.41) and with combination (OR 0.24, 0.10-0.55) compared to patients who 
did not receive either of these medications. Although this study was not a head-to-head 
comparison of ACEI/ARB with BB, but this study supports the direction of our study, since 
the risk of mortality was lowest among patients receiving BBs only compared to those not 
receiving it. This study included elderly non-hospice community dwelling Medicare patients 
taking ACEI/ARB, BB, combination or none at all in the concurrent year.  
Similarly, the article by Teng et al, assesses the trends and predictors of prescription of 
cardiac medications on discharge after the index hospitalization and their subsequent effect 
on all-cause mortality and again this study also found  a lower association of BBs with 1-year 
mortality (Hazard ratio, HR for ACEI/ARB = 0.71, p = 0.003 and HR for BB = 0.68, p = 
0.002).(Richardson et al., 2010; Teng et al., 2010) In addition, the article also concluded that 
although the use of ACEI/ARB was high over the years (1996-2000), the use of BBs showed 
an increasing trend (from 10.5% to 51.3%). This drastic increase in the utilization of BBs 
signifies BBs as an upcoming choice for HF patients. 
There are many other articles, where association of BBs in HF patients after discharge has 
been estimated. And all these articles either lack in providing a head-to-head comparison of 
ACEI/ARB with BB or they do not estimate the probability of observing the recurrent 
hospitalization.(Austin, 2009; DiMartino et al., 2010; Maison et al., 2012; Wijeysundera et 
al., 2011) Some articles have even compared ACEI/ARB vs BB for different clinical 
outcomes in a sample frame different than HF. For example, Toh et al compared the 
association between initiating on ACE, Arb or aliskiren compared to BB for the risk of 
angioedema in any adult patient (≥18 years) taking it irrespective of the disease. With BB as 
the reference group, initiating on ACEIs or aliskiren was associated with an approximately 3-
fold higher risk for angioedema.  The risk for angioedema was lower with ARBs than with 
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ACEIs or aliskiren. (Toh et al., 2012) Similarly, study by Galindo-Ocana et al. gives some 
comparative effectiveness analysis for mortality and disability progression as an outcome 
across ACEI/ARB vs BB vs their combination (i.e. ACE/ARB + BB). This study was not just 
restricted to HF patients only. The study observed that beta-blocker plus statin (HR 0.645; 
P=0.007), ACEI/ARB plus statin (HR 0.680; P=0.002), or combined ACEI/ARB plus statin 
plus beta-blocker (HR 0.541; P=0.000) prescriptions were associated with longer survival 
times implying BB as a preferable therapy when used as a combination with Statins and with 
or without ACEI/ARB. However, as monotherapy compared to no therapy, the Hazard ratios 
(HRs) across ACEI/ARB and across BB groups were 0.782(0.635-0.964) and 0.825(0.662-
1.028) respectively, implying BB as a non-preferable therapy when used as a monotherapy. 
Additionally, predictive probability for patients whose Barthel index was ≥60 showed a lower 
risk of disability progression if treated with Beta-blockers (OR=0.704; P=0.075), or their 
combinations, mainly with ACEI/ARB plus statins (OR 0.563; P=0.031).(Galindo-Ocaña et 
al., 2012) For ACEI/ARB, the OR was 0.731, p-value 0.119. Magid et al also compared 
ACEI vs BB for Hypertensive patients.(Magid et al., 2010) This study concludes that ACEI 
and BB are equally effective in lowering Blood Pressure (BP) and preventing cardiovascular 
disease and related events for patients whose BP is not controlled with Thiazide Diuretics 
alone and who have no compelling indication for 2
nd
 line agent.  
Aim and Significance of the study 
The aim of this study is to understand the impact of initiating different categories of BB 
compared to ACEI and the combination of both on risk of hospitalization in near future 
amongst HF patients. For this, a prospective observational study design on real world 
effectiveness data was used. The information from this study shall broaden the scope of HF 
treatment especially among patients for which ACEI is not tolerated and in elderly HF 
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patients with average age 73-75 years, as prevalent in HF community. Most importantly, the 
study brings evidence from real world, rather than a controlled environment of a RCT. This 
shall help us to tease out the effect of BBs from the influence of ACEI and other RAS 
inhibition. In an article by Willenheimer et al, the author has suggested that this research 
question is a challenge for the treatment of Heart disease against a background of ACEI and 
the positive result shall provide the free choice of making an individual-based judgment from 
amongst ACEI/ BB.(Ronnie Willenheimer et al., 2005) Additionally, the study has compared 
various classes of BBs compared to ACEI which is essential to decide which class of BBs to 
prefer compared to ACEI. Therefore, overall a better control of HF can be achieved 
compared to current scenario. As an indirect effect of initiating BBs before ACEI, shall also 
prevent many cases of SCD as has been established by the trials.  Once there is valid 
evidence, it will not be required to always conduct an RCT with ACEI as the standard 
therapy, which at times hinder the understanding of individual effect of new drugs under 
study in a trial. This study is one step in this regard.  
In short, the study is trying to compare time-to-first subsequent hospitalization across 
different ACEI vs different categories of BB users. The hypothesis for this study is that the 
time-to-first subsequent hospitalization for the BB group as monotherapy is at least not 
significantly different when compared to ACEI. 
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Methods 
This is a prospective cohort study using data from patients enrolled in Texas Medicare 
Advantage Prescription Drug (MAPD) plan from the year 2008-2011. This claims data 
consists of information about patient membership, member summary, institutional claims, 
professional claims, Quest lab, CCMS and Part D Pharmacy Data on computerized data files. 
The details of this data can be referred in one of our previous article. 
Ethical Considerations This study has been exempted from human studies review 
requirement by the Institutional Review Board of University of Houston. 
Study Sample 
The study sample included elderly patients (age≥ 65 years) with CHF diagnosis prior to 
therapy initiation date from a 10252 CHF patients stacked membership in MAPD data for the 
year 2008-2011.   
The details of the research design and its inclusion/exclusion criteria have been 
mentioned in one of the previous studies. In brief,  this cohort has included any alive patient 
who after ‘01July2008’, had claimed for an ACEI or a BB as a monotherapy or in 
combination in the Pharmacy Data File.(Richardson et al., 2010) These patients should have a 
diagnosis date of HF and a membership of at least 6 months prior to initiation of either 
therapy. The study has excluded patients on ARB, aldosterone antagonist or Aliskiren in the 
washout period which may otherwise bias the study.(Rashikh et al., 2012; Toh et al., 2012; R. 
Willenheimer et al., 2004; R. Willenheimer et al., 2005)  Further, BBs with 
Sympathomimetic activity (BB category 2 or BBC2) and any combination of BBs category 1 
and 3 (BBc1 and BBc3 respectively) were also excluded from the study because of its low 
sample size and for the risk of complicating the study design. All these ‘no therapies’ vs ‘a 
prescribed therapies’ in the 6 months wash out period were defined based on a cut-off of 
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proportion of days(PDC) being less than or equal to 0.04 for each drug. The details of these 
cut-off criteria, prescription drugs and the sample characteristics can be referred in the 
previous study. 
Follow-up period 
The patient was followed for 1 year from 1
st
 Jul 2008 till the last claim on 5
th
 Jan 2011.  
The follow-up time was defined as the minimum time at which either the patient switched to 
not-required drugs (ARB, BBc2, aldosterone antagonists or aliskiren) or had a death record 
on the date or reached the event time i.e. HF hospitalization or at the last record from 
pharmacy/Quest Lab/Institutional/Professional Claims file or 360 days.  
The event time is defined as the time at which either the patient was discharged from the 
first subsequent hospitalization or the time at which patient switched the therapy while still 
hospitalized. 
Outcome 
The primary outcome for this study is time-to-first subsequent HF hospitalization within a 
year from the index date (date of initiation of a therapy). The first subsequent HF 
hospitalization observed after the index date is the first HF hospitalization. In case, patient 
was hospitalized prior to or on the index date then the next hospitalization after the index date 
was defined as the first subsequent hospitalization.  All the HF hospitalizations were 
identified by the DRG codes 291, 292 and 293.("National average costs by department for 
heart failure and shock," 2010; "National average costs by department for heart failure and 
shock (revisited)," 2014; Navarro-López et al., 1997; Newhouse et al., 2003) This first 
subsequent HF hospitalization was defined by an event indicator variable or censor variable 
with value ‘1’ for the event and value ‘0’ for the censored time observed due to death or other 
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reasons of censoring including initiation of not-required drugs last claim record or completion 
of a year follow-up. 
In order to validate the model with respect to CIBIS III trial and other trials, a secondary 
outcome ‘mortality’ has also been chosen. (CIBIS III, CARMEN etc.) 
Interval observation 
The whole follow-up period is divided in interval level observations, which indicates a 
constant status of exposure to a drug or hospitalization. The censor variable for each interval 
was defined separately rather than for whole follow up time. As the interval changes with a 
change in either of the status, a start time for the next interval and a stop time for the current 
interval are defined till the follow-up time is achieved. If an event is observed in an interval 
the censor variable was indicated as ‘1’ else ‘0’ with usual meaning as defined above. The 
assumption was made that each interval censoring or event was caused by covariates and 
treatment/exposure to a drug in the previous interval and the therapy initiated on the index 
date. The information was used to develop statistical models as explained later. 
Exposure 
The treatment that the patient was getting on the index date and in the previous interval 
was defined as the exposure to drug. It could be either ACEI or BBc1 or BBc3 or a 
combination of ACEI with BBc1 (ABC1) or with BBc3 (ABC3) or a therapy other than any 
of these therapies. Thus, it’s a multinomial exposure variable. The study used a PDC based 
approach as was defined by Leslie for persistence using information about prescription claims 
and days of supply from Pharmacy file.(S. R. Leslie et al., 2008)  Each day was coded as ‘0’ 
and ‘1’ for each of the respective day. Therefore, for the index date or for an interval, the 
PDC is 100% for a particular therapy group. The strategy was used to define exposure 
therapy on the index date, also defined as initiated therapy (trt_1). Additionally, same 
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strategy was used to define exposure to drug in an interval (dg) or in the previous interval 
(prdg). The day the drug code ‘0’ was observed the interval was changed.(Powell & Bagnell, 
2012) 
Inverse Probability weight (IPW) 
The IPW was calculated using a product of the treatment, dose and censoring weight 
calculated from repeated interval observation for each person-interval as follows(Chitnis et 
al., 2012; Faries & Kadziola, 2010; Powell & Bagnell, 2012; Sugihara, 2010):- 
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Here, Dosewt was calculated as a time-varying variable for each person interval as 
follows:- 
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The censoring weight was defined as a product of deathwt (informative censoring) and 
ORCwt i.e. wt for other reasons for censoring (non-informative censoring) as 
follows(Hernán, Hernández-Díaz, & Robins, 2004; Robins & Finkelstein, 2000; Sugihara, 
2010): 
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Therefore, the IPW contains a numerator for each respective term which uses the 
respective probabilities for each term from a model that controls for gender, baseline 
hospitalization status and their count and treatment in the previous interval and no. of days of 
previous interval as a measure of exposure history. Also the model adjusted for the therapy 
each patient initiated on the index date and the time from the index date as measure of 
initiation therapy exposure duration effect. This is defined as time-fixed model. 
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For the denominator of IPW, probabilities are calculated from an equation that while 
controlling for gender, baseline hospitalization status and their count and exposure history as 
stated above and a parsimonious model of all predictors defined at each interval for the 
observations from previous interval as time-varying covariates.  This is defined as time 
varying model. Here, following 2 assumptions are made: 
 The therapy provided in each interval effects the covariates like co-
medications, cost etc. and thus varies as therapy changes with interval or time 
i.e. time-varying. 
 These time-varying covariates in an interval further affect the treatment 
provided in next interval. 
Here, treatment and dose are multinomial outcome and thus a proc GENMOD was used 
and censoring is a survival outcome and thus Phreg was used to calculate each respective 
numerator and denominator probability. (Flom, 2010; Van der Wal & Geskus, Sep 2011) 
This IPW thus obtained was adjusted for time to represent a joint probability of having 
survived the previous interval thereby controlling for the history of the current 
observation.(Cole & Hernán, 2004; Faries & Kadziola, 2010; Hernán, Brumback, & Robins, 
2000; Hernán, Brumback, & Robins, 2002; Hernán et al., 2004; Robins, Hernán, & 
Brumback, 2000) This past history adjusted weight was further normalized by count 
adjusting for sample size in respective treatment groups to obtain the final weight.(Chitnis et 
al., 2012; S. Leslie & Thiebaud, 2007) 
Except for other categories of previous drug, for which most of the covariates were 
significantly different w.r.t. ACEI and continuous variables, all other categories of drug 
provided in the previous interval showed a balance of 41-44 categorical covariates out of 44 
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categorical covariates w.r.t. ACEI with final normalized IPW history weight which indicates 
a good balance compared to unweighted data for amongst the treatment groups w.r.t. ACEI. 
Dose of drug as the time-dependent confounder 
The study by Willenheimer et al used the example from different trials to emphasize that 
there is a controversy about the association between dose and clinical outcomes.(R. 
Willenheimer, 2009) The author suggests that the CIBIS III and MOCHA trial confirm the 
utilization of higher doses of bisoprolol for reduced mortality; however, contrary to this, the 
MERIT-HF and the CIBIS II trial suggested that high and low doses of bisoprolol did not 
brought much difference in mortality.  So, this study has controlled for dose of the therapy as 
a covariate as well.  
Average dose of ACEI, BBC1, BBc3 for previous treatment provided for each interval 
were calculated. As stated previously to avoid reverse causation the model explores the 
impact of previous interval treatment and its dose on hospitalization in current interval, 
provided the patient belongs to certain therapy initiation group. 
The average dose or its transformation as log value or as quadratic term did not had a 
linear distribution, so it was categorized as No dose (<0 mg), Low dose (0-10 mg), Medium 
dose (10-25 mg) and Upper dose (>25 mg). These categories were used to calculate Dosewt. 
However, in censoring weights and also in the final model, the phreg models at various stages 
did not gave a good convergence with all these categories for ACEI, BBc1 and BBc3. So, a 
continuous dose variable for ACEI, BBc1 and BBc3 were entered in the model. 
Other time varying covariates 
All the covariates as defined at baseline as determinants of the treatment on the index date 
were redefined for each interval for the duration of previous interval. This means the 
covariates observed in the previous interval determines the treatment provided in that 
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interval. For example the lab values observed in the previous interval will determine which 
therapy will be provided in that interval. Apart from that other covariates as defined under 
IPW were also defined for each interval and entered in the IPW and final Phreg model. 
Statistical Analysis 
A series of models were developed to explore all possibilities. Initially, an Unadjusted 
Kaplan Meier curve, Schoenfeld residuals and log rank test were developed for the person-
interval data to test the proportionality hazard assumption. The Univariate model here 
controlled for initiated therapy (trt_1) only and has been defined as Model 1 for further 
reference. In this model, a patient was followed for the duration as long as the patient is on 
one of the either treatment groups with or without switching. The model was developed to 
represent the effect of censoring in current interval w.r.t. the effect of therapy provided on the 
index date i.e. ‘Initiated Therapy’ (trt_1). 
Similarly, another Univariate model using normalized IPW weight defined effect of 
initiated therapy in Model 2.(Robins & Finkelstein, 2000) The study develops a count based 
extended-cox-regression model to identify the time-to-first subsequent hospitalization. The 
article by Powell et al recommends that count process (CP) approach for time-varying 
covariates yields similar results compared to an extended cox model.(Powell & Bagnell, 
2012) Robust estimates were obtained and COV (AGGREGATE) allowed defining the 
covariance structure of the repeated data. 
Further a fully adjusted weighted CP model (referred as Model 3) was developed similar 
to model 2 by including all variables as defined above.  Additionally, the therapy provided in 
the previous interval (prdg), its duration and average dose was also included. The model also 
includes the variables to define the duration of the first interval for each of the index therapy 
for the model and its average dose.  
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It is important to note here that none of these models control for the effect of current 
therapy on current interval censoring to avoid the possibility of reverse causation bias. And as 
stated above, they represent the effect of Initiated therapy on censoring, while allowing 
switching of the therapy in each interval compared to previous interval.  
The results of these 3 switching models were compared with the baseline Cox model with 
baseline covariates only and not allowing switching i.e. patients were censored as soon as 
they made the switch to a treatment group different than the one on the index date.  This was 
labeled as Model 4. Additionally, the same baseline Cox model without switching and 
labeled as Model 5 was developed after removing patients who did not received the treatment 
for first 14 days after the index date, i.e. PDC ≤ 0.2 for a whole year of 360 days.  For these 
data, a count model was not developed because log rank was non-significant for baseline Cox 
model without switching (p-value 0.3942 and p-value 0.4003). 
For secondary outcome of mortality, a baseline Cox model with baseline covariates only 
and without allowing switching (Model 6) was developed along with another baseline Cox 
model without allowing switching (Model 7)  developed after removing patients who did not 
received the treatment for 14 days after the index date of initiating the treatment. 
All analyses were performed at a significance level of p-value ≤ 0.05 using Statistical 
Analysis Software (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).  
Sensitivity analysis for Change in length of follow-up 
 Results re-analyzed for change in follow-up time period from 1-year to 2-years. This is 
because, as reported previously, in the trial by Sliwa et al. as the length of follow-up 
increased for an additional 6 months, the results became in favor of BBs.(Sliwa et al., 2004) 
Further, in CIBIS-III trial also, one major limitation described was the length of follow-up 
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time and it was suggested that BBs take some time to show their beneficial effect. (R. 
Willenheimer et al., 2005) 
Subgroup analysis  of Ejection Fraction 
A claims-based definition based of systolic dysfunction  was used to identify patients in 
whom the EF was <45%.(Setoguchi et al., 2011) The definition required that there have been 
no diagnosis of atrial fibrillation (ICD-9-CM code 427.31) and had received Digoxin during 
the 180 days before the index date, which for this study is the therapy initiation date.(Jensen 
et al., 2012; Setoguchi et al., 2011) This definition had a positive predictive value of 87% for 
identifying patients with EF <45% in the.(Setoguchi et al., 2011) 
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Results 
There were 248 (3.87%) first subsequent hospitalizations in the cohort of 6430 elderly HF 
patients. At interval level these observations gave 18176 person-interval observations in the 
cohort with 1.36% of event intervals of first subsequent hospitalization. Table 1 compares the 
frequency distribution of initiated therapy at person level as well as at interval level. Table 2 
represents the censored events observations with regard to the therapy initiated at patient 
level. Apart from other therapeutic group, the highest percentage of censored observations 
was observed for BBc1 (0.92%). 
The Kaplan-Meier plot for unadjusted unweighted person-interval data is represented in 
Fig 2.  This represents maximum survival probability for patients initiating ACEI and lowest 
for BBc3 groups at different stop points where interval ends. None of the survival probability 
curves were found to follow proportional hazard assumption with respect to ACEI as also 
confirmed by the log rank test (p<0.0001), thereby confirming lack of proportionality hazard 
assumption at least for one treatment group. 
Table 3 compares the result of all the Hazard Ratios and their respective 95% Confidence 
Interval across Model 1- 5 for the risk of first subsequent hospitalization. The results from 
sensitivity analysis in this regard are also demonstrated. The result demonstrates that in 
Model 3 after controlling for dose and other factors along with past history at a given interval 
the initiation on BBc1 and BBc3 gave a non-significant effect compared to initiation on 
ACEI. In Model 5 compared to Model 4, adjusting for covariates and ensuring at least 14 day 
medication removed significant variation from BBc3 and made it non-significant compared 
to ACEI. The therapeutic groups of BBc1 as monotherapy and as combination gave non-
significant hazard ratio in all the models. Compared to Models 1-3 that allowed switching, 
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the hazard ratios for Model 4 and 5, that did not allowed switching, had higher hazard ratios. 
In model 5, no hazard ratio was obtained for the ABC3 group due to lack of observation of 
the event. The table also presents the results of sensitivity analysis for data followed for 2 
years rather than 1 year. It provides a non-significant hazard ratio for all groups except for 
other therapy group.  Table 4 compares the Hazard ratios for mortality and their respective 
95% Confidence Interval across Model 6 and 7 along with estimates from sensitivity analysis. 
Neither of the models gave a significant hazard ratio for mortality for any of the initiated 
therapy. No Hazard ratios were obtained for a combination of ACEI and BBc1 due to lack of 
observation of mortality in the treated group for both models as well as for sensitivity 
analysis data.  
Table 5 represents the data for subgroup analysis for patients with EF<45% as defined 
based on claims databased operational definition from past literature. It indicates that in 
patients with EF<45% maximum patients initiate on ACEI and these users are even higher 
than the other therapy group. Of all the events of first hospitalization, maximum events were 
observed amongst ACEI users. Of all events 38.46% were amongst ACEI users, 30.77% 
amongst BBc1 users, 7.69% amongst BBc3 users and 23.08% amongst other therapy users. 
No events were observed amongst combination therapy group. None of these groups showed 
mortality events except for the other therapy group which had 6 events of mortality. 
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Discussion 
The above results indicate that for BBc1 a statistically non-significant effect was 
observed in all the models compared to ACEI. Thus, the results imply an observed non-
significant difference in the effect of the 2 drugs for first hospitalization. These estimates of 
first HF hospitalization for BBs are lower than compared to those from CIBIS III trial. The 
trial reported a Hazard ratio for Worsening of Heart Failure (WHF) defined for events 
occurring while in hospital to be 1.25(95%CI: 0.87-1.81) and all-cause hospitalization was 
0.95(95% CI: 0.76-1.19).(R. Willenheimer et al., 2005) These estimates appear to be close to 
univariate model, which despite not controlling for severity and other covariates showed 
BBc1 to be non-significantly different than ACEI. This observation probably could be 
accounted for the fact that the trial result for WHF focus only on a severe condition, which 
justifies this being higher than the first HF hospitalization defined here; the latter being a 
composite of severe and mild HF hospitalization. Similarly, all-cause hospitalization includes 
any possible cause of hospitalization and not just HF hospitalization, which again ought to be 
higher than HF hospitalization. Thus, results of our study seem to be in agreement with the 
CIBIS III trial. 
For BBc3, Univariate models (1 and 2) along with the baseline adjusted Cox model 
(Model 4) gave a significantly high hazard ratio. However, with adjustment for covariates 
from the previous interval in the Model 3 including the treatment provided in the previous 
interval the difference in the effect became non-significant. This indicates the importance for 
controlling the history. Contrary to this in model 4 only baseline history was controlled for 
since throughout the follow-up time period the treatment did not changed. In this model, it is 
the sole effect of one treatment. This demonstrates a significantly high effect of BBc3 
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compared to ACEI. However, when the analysis was restricted to patients who took the drug 
for at least 14 days from a year follow-up then again the difference became non-significant 
compared ACEI. This indicates 2 possibilities. First these drugs take some time to show its 
effect as could be expected and also as anticipated in the CIBIS III trial.(R. Willenheimer et 
al., 2005) However, on comparing the estimates of model 3, i.e. 1 year data, with sensitivity 
analysis i.e. 2-year data, it is observed that the BBc3 estimates from both the models are close 
enough and thus it rules out this possibility. Second reason could be the fact that the initial 14 
days were severe patients, although the history of patient was controlled for the observed 
duration but there could be some difference in the 2 treatment groups due to some 
unobserved variation. This difference was not observed in the Model 3 where similar to this 
model all patients were included and where by means of weighing the past history a balance 
in the treatment groups was achieved. So, as soon as these patients were excluded in Model 5 
the difference in the hazard ratio for BBc3 and ACEI became non-significant.  From the 
frequency distribution analysis of the hospitalization in the 2 cohorts (results not shown), it is 
observed that there were 7 first subsequent hospitalization for the BBc3 in Model 4 out of 
total 112 events i.e. 6.25% as opposed to 6 events from total 110 events i.e. 5.45% of total 
events in the cohort for Model 5. This means there is a decrease of 0.8% indicating a decrease 
in the severity in Model 5 compared to Model 4 thus supporting the possibility.  
The CARMEN trial reported 10% cardiovascular hospitalization with BBc3 as opposed to 
15% with ACEI.(Komajda et al., 2004) Similarly, this study found 18.15% of first HF 
hospitalization for ACEI compared to 16.53% of all HF hospitalization for BBc3, although 
little higher ratios compared to the trial but they seem to follow similar trend. The slight high 
percentage of HF hospitalization observed in this study could be attributed to the fact that the 
population included in this study is at least on average 10 years older compared to those of 
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the trial. This again emphasizes the need to include community population in a study unlike 
RCTs. 
Further the hazard ratios for BBc3 are higher compared to BBc1. This is in contradiction 
to what previous literature predicts. However, it is possible to see some variation when a 
direct comparison is made. Additionally, a low sample size of BBc3 could be an issue here. 
However, this needs to be tested. Further, the hazard ratio for combination of ACEI and 
BBc3 are low or at least comparable when compared to BBc1 estimates or for BBc3 as 
monotherapy in Model 3, 4 and 5 and for sensitivity analysis. The combination seems to 
simulate a condition similar to that in a trial, where BBs are always provided with ACEI as a 
standard therapy and based on this trials adjudicate for providing BBc3 i.e. Carvedilol to be a 
better therapy. In this study, a clear distinction has been provided between a combination 
therapy and a monotherapy. And if as suggested earlier, the trial therapy in essence is a 
combination therapy of any BB with ACEI and if the results of this study are in accord with 
the trial then it can be inferred based on Model3-5, on sensitivity analysis and on trials that 
the combination of ACEI and BBc3 is a better therapy compared to the combination of ACEI 
and BBc1. Contrary to that this study shows that for the first hospitalization as the outcome 
the monotherapy of BBc1 has an upper hand compared to BBc3 in all the models, which till 
date has not been conveyed in the trials. The unadjusted Kaplan Meier plot also supports this 
observation. Further the combination of ACEI and BBc1 does not seem to provide any 
distinct benefit when compared to monotherapy of BBc1 for Model 3 and sensitivity analysis. 
For Model 4 and 5, the estimates have very wide confidence interval to justify any comment 
about the significant difference of BBc1 as monotherapy or as combination. So, it seems 
more reasonable to suggest BBc1 as monotherapy rather than as its combination with ACEI 
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in elderly HF patients who are already under load of polypharmacy.(Powlson, 2003; Volpe, 
Chin, & Paneni, 2010) 
It can be argued that when in comparison to the results of Model 3 (1-year data) the 
estimates of BBc1 in sensitivity analysis (2-year data) increased drastically. Although the 
confidence intervals suggest that this difference could be non-significant; despite that it could 
raise a doubt if BBc1 in 2
nd
 year is worsening the effect. On the other hand, BBc1 as 
monotherapy seems to provide nearly constant effect. Also it should not be overlooked that 
despite a questionable increase with BBc1 in 2
nd
 year, it was still lower than that of BBc3 as 
monotherapy for 2
nd
 year or at least statistically non-significant for 2
nd
 year. This suggests 
that if patients initiate with BBc1 for first year the effect is comparatively better but the 
estimates could possibly increase slightly for second year. 
The last group studied in this study was other therapy group. This group is heterogeneous 
in terms of patients included in this group. It includes patients who did not receive any 
therapy and also the patients who might have received some therapy other than ACEI or BBs 
as monotherapy or as combination. This group was included to cover the possibility of 
allowing switching to some therapy other than ACEI or BBs as monotherapy or as 
combination. The heterogeneity of this group from other groups was not balanced in the 
weighing process, which could imply unreliability of results from model 3 for this group. 
However despite that in any of the adjusted model hazard ratio for first subsequent 
hospitalization was significantly high compared to ACEI. To provide a definitive conclusion 
about this group it would be advisable to study varied possibilities of the treatments that 
could be initiated here.  
The variation observed in the results for model that allow switching (Model 3) vs. the 
models that do not allow switching (Model 4 and 5) is also interesting. Table 3 demonstrates 
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the findings. It can be argued that without switching a higher hazard ratio is observed 
compared to when switch was permitted in the model. However, our focus of discussion is 
the effect of initiated therapy rather than the current therapy. As already argued and as also 
suggested by CIBIS III trial, the hypothesis is to prove that sooner patients start on BBs 
compared to ACEI, sooner protective effects may be achieved..(R. Willenheimer et al., 2004) 
In fact in the trial, patients initiated on one therapy for 6 months and later switched to their 
combination of both therapies. In Sliwa et al too, initially patients were prescribed 
monotherapies of ACEI and BBc3 for first 6 months and then later combination was 
prescribed to both groups.(Sliwa et al., 2004) Despite that the effect of group initiating with 
BBc3 became more prominent in favor of BBc3 group compared to ACEI even after long 
time after the switch was made. The authors have concluded that it’s the effect of therapy that 
patients initiate on which plays major role in influencing current LVEF and NYHA 
Functional class. This is because this therapy is able to achieve optimum and a higher dose. 
In real world also, it is quite possible that patient will switch to another therapy. But then the 
effect of therapy that was initiated always imposes some influence on further course of the 
treatment. This study supports this hypothesis in all the models with or without switching. 
The study also presented the mortality results from baseline Cox models, which again 
supports the possible statistically non-significant effect as is also observed in the trials. The 
results were generated to validate the findings from our study in comparison to the trial and 
other past literature. The result seems to be in agreement with the study by Richardson et al 
which reported an odds ratio of 0.24 (95%CI: 0.11-0.50) for ACEI vs 0.17 (95%CI: 0.07-
0.41) for BBs alone and with combination it was 0.24 (95%CI: 0.10-0.55). The study by Teng 
et al reported a Hazard ratio for mortality of 0.71 (p-value = 0.003) for ACEI/ARB and an 
HR for BB of 0.68 (p-value = 0.002).(Richardson et al., 2010; Teng et al., 2010) The results 
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seem to be in congruence with the trial as well. The CIBIS III trial demonstrated tendency 
towards less sudden death (HR 0.50; 95% CI 0.21–1.16, p=0.11) and all cause death (HR 
0.88; 95% CI 0.63-1.22) with bisoprolol-first group compared to enalapril-first 
group.(Remme, 2008; R. Willenheimer et al., 2005)  The CARMEN trial did not report a 
hazard ratio for any of the clinical outcomes. However, it reported a rate of 7% for all-cause 
mortality (7%) and respective rates of 7%, 7% and 5% for cardiovascular mortality for ACEI, 
BBc3 and their combination; again proving a statistically non-significant difference in effect 
of ACEI and BBc3 and better protection from combination therapy.(Komajda et al., 2004) 
An interesting observation that has been made here from 1-year data vs. 2-year data is 
that the estimates increased for the latter compared to 1-year data. If we recall the findings of 
our previous study, it was suggested that as duration of HF increases, the likelihood of 
initiating BBs decreases compared to ACEI. And current study suggests that as this 
likelihood decreases or as the duration increases the estimates of first hospitalization 
increases slightly. This means that the initiation therapy is important but its effect probably 
wears off after a year, which is a long time in itself to change many conditions. 
Limitation  
Some of the limitations of the cohort have already been discussed elsewhere. Briefly, 
there could be coding issues inherent to claims database and a lack of direct measure of 
severity and random assignment to different treatment groups. The study does not 
discriminate if ACEI vs BB vs combination was used as first line or 2
nd
 line or 3
rd
 line 
therapy, which included only JNC approved drugs.  
In addition to this there is a measurement of exposure assumed to be proportionally the 
same in all the treatment groups for example due to insufficient follow-up time a non-
differential measurement of exposure can be expected. May be all or some of the therapies 
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are in therapy-initiation phase and have not reached proper maintenance dose. To avoid this, 
patients were followed for a defined period based on past literature. The effect of strictly 
including patients who took the drug for at least 14 days in model 5 also assures some time 
on these therapy before their results can be compared. Additionally a sensitivity analysis was 
done to assess the effect of longer follow-up period.   
The study could not provide the effect of BBs with sympathomimetic activity i.e. BBc2, 
effect of adherence and the effect of some important covariates like race. These should be the 
focus of future studies before generalizing the results to all elderly HF patients. 
Strength 
1. One of the greatest strengths of this study is the strong operational definition of 
exposure of the treatment on the index data and also during any interval. The 
technique used in this study based on PDC has helped to provide 100% persistence 
rate of a therapy on the index date as well as during an interval. This makes the 
comparison strong and avoids the variation in therapeutic group due to differences in 
adherence rate. 
2. It controls for the influence of dose too. The CIBIS III trial used an open design 
where the titration schedule was dependent on the tolerability of each individual and 
their response to treatment.(R. Willenheimer et al., 2004) In real life, this situation is 
the driving factor for switching of the therapies. 
3. It provides information for ACEI/BB as monotherapy and as combination both, and 
not just of monotherapy. In CIBIS III trial, the author suggested that the first initiated 
therapy like ACEI or BB, stands the better chance to be given long term and in 
adequate dose.(R. Willenheimer et al., 2004) However, our study has included 
patients on each therapy with doses as prescribed in real world. In real-world doses 
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are adjusted as per the tolerability of the patient and thus their up-titration may be 
different than that applied in a controlled environment of an RCT. For example, here 
already a minimum tolerable limit and optimum standard dose is known, so 
prescribers may have a different starting dose compared to that used in a RCT.  
4. Sensitivity analysis tests the results for initiating ACEI/BB/combination therapies for 
a longer duration, which is essential as suggested by previous trials for BBs to show 
their optimum effect(Sliwa et al., 2004; R. Willenheimer et al., 2005). 
5. The use of available lab values at various time points minimizes confounding by 
indication. Although there are lots of missing information in these variables, but this 
is expected as also suggested by Schneeweiss.(Schneeweiss et al., 2012) Further using 
LOCF, these possibilities of missing values was reduced. Weighing the history of the 
observation also helped to reduce the effect of missing information. And finally, any 
missing observation was not discarded from the study; rather it was included as a 
‘Missing value’ category to extract whatever possible information could be found 
from the study. 
6. The class effect of different BBs has been compared here, which is difficult in RCTs. 
This provides additional information to clinicians which look out for therapeutic 
equivalent drugs to replace one. 
7. The study provides evidence for all types of HF patients and not just those with LVEF 
<35% as chosen in CIBIS III trial.(R. Willenheimer et al., 2004) As already stated, 
beta-PRESERVE trial is trying to target effect of using BBs in HFNEF patients too, 
our study provide some evidence with regard to those population and may support the 
need for the trial for all types of population for HF and thereafter, modification in 
guidelines.(Zhou et al., 2010) 
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8. With double weighting and Covs(aggregate) the complex nature of the treatment was 
incorporated in this study which often is affected by the death/switching/other causes 
of drop-outs as the terminal event and also by considering that measures on one 
person are correlated in nature. This helps to bring the data and its analysis close to 
reality. 
9. The Inverse probability weights helped to balance various treatment groups for at 
least the categorical covariates with respect to the reference category, thereby 
strengthening the causal design. 
10. By comparing the results of the switching model with models without switching, a 
comprehensive comparison of the effect of the treatment has been provided. 
11. Further, use of multiple controls like other therapies along with nested nature of the 
data in the switching count process model helps to control for any overt bias. For this 
model, results are also obtained by cross-comparison across same patient on different 
treatment which provides advantages similar to cross-over designs along with cohort 
population. 
The strength of this study is evident from the closeness of the findings with the trial. 
Additionally some new estimates were assessed here which were not studied previously. 
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Conclusion 
The results indicate a possible statistically non-significant effect of ACEI and 
BBc1/BBc3 as monotherapy and as combination on first subsequent HF hospitalization and 
mortality. BBc1 as monotherapy seems to be a preferable therapy compared to its 
combination with ACEI or compared to BBc3 as monotherapy. From amongst combination 
therapies, combination of ACEI and BBc3 seems to be a preferable therapy. BBc1 as 
monotherapy or as combination showed low or none mortality events respectively compared 
to BBC3. 
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Appendix 
Fig 1 Study Design 
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Figure 2.  Kaplan-Meier Plot for Unadjusted unweighted survival probabilities for first hospitalization after initiating a treatment 
on the index date for person-interval data 
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Table 1. Frequency distribution of the treatment Initiated on in the cohort at patient level vs person-interval 
level 
Treatment Initiated (trt_1) Patient level Person-Interval level 
Frequency Percent Frequency Percent 
ACEI 1194 18.57 5226 28.75 
BBc1: BBs 1519 23.62 6210 34.17 
BBc3: Combined alpha and BBs 490 7.62 2059 11.33 
Combined ace and BBc1 257 4 1224 6.73 
Combined ace and BBc3 126 1.96 528 2.9 
Other Therapies 2844 44.23 2929 16.11 
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Table 2. Frequency distribution of all 248 Censored Observations across each initiated 
therapy(trt_1) 
Treatment Initiated (trt_1) Patient level 
Frequency Percent 
ACEI 45 0.70 
BBc1: BBs 59 0.92 
BBc3: Combined alpha and BBs 41 0.64 
Combined ace and BBc1 11 0.17 
Combined ace and BBc3 7 0.11 
Other Therapies 85 1.32 
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Table 3. Comparison of Hazard Ratios for first subsequent hospitalization due to initiation therapy across Models 1 to 5 and 
Sensitivity Analysis 
HR(95% CI: Lower CI-Upper CI) 
Obs Initiated 
Therapies 
HR1 HR2 HR3 HR4 HR5 Sensitivity 
Analysis 
1 BBc1: BBs 1.054 
( 0.715- 1.553) 
1.009 
( 0.651- 1.564) 
0.562 
( 0.278- 1.134) 
2.169 
( 0.478- 9.836) 
2.171 
( 0.446-10.557) 
0.971 
( 0.473- 1.994) 
2 BBc3: Combined 
alpha and BBs 
2.39 
( 1.566- 3.65) 
3.501 
( 2.114- 5.798) 
1.242 
( 0.636- 2.426) 
5.269 
( 1.081- 25.679) 
4.117 
( 0.89- 19.054) 
1.303 
( 0.688- 2.465) 
3 Combined ace and 
BBc1 
1.12 
( 0.579- 2.165) 
1.562 
( 0.736- 3.316) 
1.052 
( 0.409- 2.706) 
1.424 
( 0.22- 9.221) 
1.396 
( 0.212- 9.171) 
0.94 
( 0.449- 1.965) 
4 Combined ace and 
BBc3 
1.497 
( 0.675- 3.319) 
2.221 
( 0.85- 5.802) 
0.632 
( 0.223- 1.793) 
1.155 
( 0.122- 10.959) 
 0.536 
( 0.19- 1.509) 
5 Other Therapies 0.88 
( 0.613- 1.264) 
0.469 
( 0.311- 0.708) 
0.211 
( 0.114- 0.39) 
3.467 
( 1.106- 10.866) 
3.549 
( 1.062-11.862) 
6.91 
( 3.137- 
15.221) 
HR1 = Hazard ratio for Univariate Unweighted Count Model with switching (Model 1) 
HR2 = Hazard ratio for Univariate Weighted Count Model with switching (Model 2) 
HR3 = Hazard ratio for Weighted Adjusted Count Model with switching (Model 3) 
HR4 = Hazard ratio for Unweighted Baseline Adjusted Cox Model without switching (Model 4) 
HR5 = Hazard ratio for Unweighted Baseline Adjusted Cox Model without switching for patients who took initiated therapy for at least 14 
days (Model 5) 
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Table 4. Comparison of Hazard Ratios of Mortality due to initiation therapy across Models 6 and 7 and for Sensitivity Analysis 
HR(95% CI: Lower CI-Upper CI) 
Obs Initiated Therapies HR6 HR7 Sensitivity Analysis 
1 BBc1: BBs 0.212( 0.028- 1.6) 0.212( 0.028- 1.598) 0.369( 0.023- 6.001) 
2 BBc3: Combined alpha and BBs 1.071( 0.107- 10.716) 1.069( 0.107- 10.701) 1.882( 0.095- 37.089) 
3 Combined ace and BBc1 - - 0 
4 Combined ace and BBc3 1.324( 0.115- 15.209) 1.316( 0.115- 15.122) 4.4( 0.28- 69.249) 
5 Other Therapies 1.258( 0.279- 5.669) 1.252( 0.277- 5.647) 1.534( 0.144- 16.349) 
 
HR6 = Hazard ratio for Unweighted Baseline Adjusted Cox Model for mortality without switching (Model 6) 
HR7 = Hazard ratio for Unweighted Baseline Adjusted Cox Model for mortality without switching for patients who took initiated therapy for 
at least 14 days (Model 7) 
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Table 5 Sub-group Analysis of the treatment groups being compared for patients with EF<45% 
S.No. Initiated Therapy(Trt_1) Freq (n = 160) 1
st
 Hosp. (n = 13, 8.13%) Mortality 
1. ACEI 52 (32.5%) 5(38.46%) 0 
2. BBc1 46 (28.75%) 4(30.77%) 0 
3. BBc3 15 (9.38%) 1 (7.69%) 0 
4. ABC1 4 (2.5%) 0 0 
5. ABC3 2 (1.25%) 0 0 
6. Other Therapies 41 (25.63%) 3 (23.08%) 6 
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Manuscript #3 
Risk of Recurrent Hospitalization among Elderly Heart Failure Patients initiating 
Angiotensin-Converting Enzyme Inhibitors(ACEI) or Beta-Blockers(BBs) - a 
comparative effectiveness analysis 
 
Finding: The results indicate a non-significant effect of BBc1 and BBc3 in comparison to 
ACEI on recurrent HF hospitalization and composite outcome. 
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Abstract 
Objective: To estimate the effect of initiating Beta-Blockers(BBs) vs. Angiotensin-
Converting Enzyme Inhibitors(ACEIs) among elderly Heart Failure(HF) patients for the risk 
of recurrent HF hospitalization and for the risk of composite outcome of HF hospitalization 
with death as the terminal event. 
Methods: Using elderly (age≥65 years) HF patients initiating ACEI or a category 1 
BB(BBc1) and category 3 BB(BBc3 i.e. BBs with combined alpha and beta blocking 
activity), were identified from Medicare Advantage Prescription Drug Plan(MAPD) Data 
2008-2011. The survival probabilities of recurrent HF hospitalization and of composite 
outcome of HF hospitalization with death as the terminal event were obtained by the inverse 
probability weighted stratified total time and gap model and by the marginal model 
respectively for a follow-up of a year using SAS 9.3 at the p-value of 0.05. 
Results: There were 248 (3.86%) recurrent hospitalization patients with 331 recurring 
events in the cohort of 6430 elderly HF patients. The hazard ratio for recurrent HF 
hospitalizations were 0.969(95%CI: 0.47- 1.996) and 1.32(95%CI: 0.702- 2.483) and for 
composite outcome were 0.871(95%CI: 0.51- 1.48) and 1.41(95%CI: 0.84- 2.36) for 
respective initiation therapies as BBc1 and BBc3 with respect to ACEI. 
Conclusions:  The results indicate a non-significant effect of BBc1 and BBc3 in 
comparison to ACEI on recurrent HF hospitalization and composite outcome. 
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Introduction 
Heart Failure (HF) has been a challenge with a high prevalence rate of more than 5.5 
million adults in US as per 2009 report, of which 10 per 1000 were over 65 years of 
age.(Shafazand et al., 2010) Treatment of the disease requires prescription of angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for requires for 
stage A HF (mild HF or patients at risk of HF) and if they also have vascular disease or 
diabetes.(Shafazand et al., 2010) For stage B HF (i.e. mild to moderate HF), Beta-Blockers 
(BB) may be added. These recommendations are made by the American College of 
Cardiology and the American Heart Association (ACC/AHA) 2005 and even by the 2013 
ACC/AHA HF guidelines.(Hunt et al., 2009; Yancy et al., 2013) Despite these 
recommendations by the guidelines, discussion is on-going regarding the benefits of an early 
start of BBs even before ACEI. This has been attributed to the evidence from the recent trials 
which suggest that BBs plays an important role in reducing the risk of Sudden Cardiac Death 
(SCD), ischemia and cardiac remodeling by virtue of their rapid activation of sympathetic 
and renin angiotensin system (RAS) compared to when ACEI is administered first. (Remme, 
2007, 2008). Additionally, a higher dose of BB can be administered and an increased RAS 
activation is achieved due to increased Na and water retention and a diminished level of 
serum creatinine.(Knight et al., 1999)  
A brief review of all the important clinical trial has been presented in one of the previous 
studies. It demonstrates examples from trials like Sliwa et al, CARMEN trial, CIBIS III trial 
etc. which respectively demonstrated the beneficial or statistically non-significant effect of 
BBs compared to ACEI amongst patients with idiopathic dilated cardiomyopathy for 
carvedilol (BB category 3 drug as per JNC guideline, i.e. BBc3), for patients with increased 
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cardiac remodeling for carvedilol and for patients requiring all-cause/cardiovascular 
hospitalization for bisoprolol (BB category 1 drug as per JNC guideline, i.e. BBc1).(Komajda 
et al., 2004; Remme, 2007, 2008; Remme et al., 2004).(Flather et al., 2005; Remme, 2008; R. 
Willenheimer, 2009; R. Willenheimer et al., 2005)  At the same time, the beta-PRESERVE 
trial is trying to test metoprolol succinate (BBc1) across various clinical outcomes for HF 
with normal left ventricular ejection fraction (HFNEF) in a multicenter trial, thereby 
broadening the spectrum of BBs not only for patients with high LVEF but also for patients 
with Normal EF.(Morrissey et al., 2011; Zhou et al., 2010)   
Although the existing evidence from RCTs establishes BBs as a promising therapeutic 
group for HF patients but there is still a need for generating the generalizable strong evidence 
regarding the comparative effectiveness of ACEI vs. BBs. The probable reason for this gap as 
suggested in past literature is that till date majority of the trials conducted so far have tried to 
compare only ACEI with placebos before even thinking about BBs trials.(Cruickshank, 2000; 
Gheorghiade, Colucci, & Swedberg, 2003; Remme, 2007; Remme et al., 2004) The ample of 
evidence generated in favor of ACEI against placebo made it a standard therapy for 
conducting a HF trial. Even when BB trials were conducted ACEI was part of approximately 
90% of the trial’s patient population e.g. SENIOR trial which makes it hard to attribute the 
protective effect of the trial solely to beta-blockade.(Flather et al., 2005; Remme, 2007, 2008)  
This especially poses a challenge for treating elderly patients with BBs. Although these trials 
target elderly HF population but the included patients are comparatively younger volunteers, 
thereby providing results on a biased population.(Richardson et al., 2010) The CIBIS III trial 
tried to include this population but the trial does not address the safety and efficacy of BB for 
elderly patients’ clinical end-points. And this trial used up most of the time for initiation and 
up-titration of bisoprolol, so despite WHF being the underlying phenomenon for introducing   
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BBs among HF patients, the trial is not considered a good setting to answer the research 
question.(Remme, 2007, 2008; R. Willenheimer et al., 2005)  
Further, studies have also reported that the effect of BBs varies with the type of BB under 
scrutiny.(Aronson, 2008) This makes it difficult to generalize the findings. For example, 
COMET trial showed greater reduction in fatal and non-fatal MIs and SCD due to carvedilol 
treatment compared to metoprolol treatment (Beta-1 selective agent or BBc1).(Poole-Wilson 
et al., 2003) Bisoprolol has a similar profile as of metoprolol. This may imply that the type of 
BB is an important factor in revealing  the most effective BBs of all or for comparing these 
BBs with another class of drugs like ACEI in this case. Thus there exists a gap in the 
literature which demands us to bring more evidence in this regard. However, despite our 
desire for conducting a RCT, its cost, time and other practical limitations makes RCTs 
practically an infeasible design approach. Additionally, it is difficult to compare all or even 
more than 2-3 BBs with another anti-hypertensive class in a single trial. And therefore, there 
is a need to think of alternative research strategies like observational studies before planning 
for RCTs.  
Till date, none of the existing observational studies have provided a direct head-to-head 
comparison in this regard. However, based on some observational studies like Richardson et 
al, Teng et al etc. which compare association of BBs with mortality or a clinical outcome 
other than recurrent hospitalization in HF patients after discharge, the evidence again seem to 
support the direction of the research hypothesis of this study.(Richardson et al., 2010; Teng et 
al., 2010; Toh et al., 2012) However, these studies either lack in providing a head-to-head 
comparison of ACEI/ARB with BB or their sample frame is different than HF for example 
studies like Toh et al which tests these patients for angioedema patients or study by Galindo-
Ocana et al explores a cohort of any patient on these drugs.(Austin, 2009; DiMartino et al., 
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2010; Maison et al., 2012; Wijeysundera et al., 2011).(Richardson et al., 2010; Teng et al., 
2010) (Toh et al., 2012) Similarly, the study by Magid et al also compared ACEI vs BB for 
Hypertensive patients.(Magid et al., 2010) This study concludes that ACEI and BB are 
equally effective in lowering Blood Pressure (BP) and preventing cardiovascular disease and 
related events for patients whose BP is not controlled with Thiazide Diuretics alone and who 
have no compelling indication for 2
nd
 line agent. None of them provide an estimate of the 
probability of observing the first hospitalization or recurrent hospitalization.  
Based on past literature, it has been speculated that with the change in type of BB (from 
bisoprolol to carvedilol i.e. from BBc1 to BBc3), there is a possibility that the results of 
CIBIS III trial may change, especially for hospitalization due to WHF. However, to establish 
this difference in WHF across different BB categories compared to ACEI or their 
combination, the data used in this study does not have any direct measure. To deal with this 
issue, an approach similar to the SHIFT trial was followed. In this trial, WHF was assessed as 
risk of potential recurrent hospitalization as a measure of WHF and it calculated the time-to-
first, second, third and subsequent repeated hospitalization,  and the gap between each of 
these subsequently repeated hospitalizations.(Borer et al., 2012)  
With these facts evident to us, this study aims to understand the impact of initiating 
different categories of BB compared to ACEI and the combination of both on risk of 
recurrent HF hospitalization in near future amongst HF patients. HF patients are at high risk 
of repeated hospitalization. If it can be proved that hospitalization and re-hospitalization are 
comparable across ACEI vs different categories of BB, then in true sense the non-significant 
difference of the 2 drugs can be established.  But most studies as mentioned above either 
compare first hospitalization or they study about all-cause hospitalization. The information 
from this study shall overcome this gap and provide an estimate of repeated risk of 
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hospitalization. The information can be beneficial in situations where ACEI is not tolerated 
and in elderly HF patients with average age 73-75 years, as prevalent in HF community. 
Since the evidence in this study are from real world, rather than from a controlled 
environment of a RCT, the study can provide us the preliminary evidence with regard to the 
sole effect of BBs distinguished from the influence of ACEI and other RAS inhibition. 
Additionally, the study has compared various classes of BBs compared to ACEI which is 
essential to decide from amongst interchangeable therapeutic classes. Therefore, the study 
can provide a hope towards a better control of HF compared to current scenario not only by 
preventing hospitalizations but also by preventing many cases of SCD as has been established 
by the trials.  Once there is sufficient evidence the results can be validated in an RCT with 
ACEI. This study is one step in this regard.  
 
In short, the study is trying to compare time-to-recurrent HF hospitalization across ACEI 
vs different categories of BB users. The hypothesis for this study is that the time-to-recurrent 
hospitalization for the BB group as monotherapy is at least not significantly different when 
compared to ACEI. 
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Methods 
This is a retrospective cohort study that includes elderly Medicare Advantage Prescription 
Drug Plan (MAPD) patients in Texas region for the year 2008-2011. The data is collected by 
the Centers for Medicare and Medicaid Services (CMS).   
The details of this claims data have been provided elsewhere. This study has used 
information about patient membership and member summary for demographics, CMS risk 
score, cost and type of visit or admission made for each year. The Institutional and 
Professional claims files, Quest lab files and Pharmacy files were used to extract information 
on inpatient and outpatient claims, lab tests and drug identifying and related information 
respectively. 
Ethical Considerations This study is exempted from human studies review requirement 
by the Institutional Review Board of University of Houston. 
Study Sample 
The study stacks all 10252 HF patients from MAPD 2008-2011 data as existing in  
community, in long-term care facility or in hospice program and HF patients diagnosed by 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
codes 428.xx, 401.x1, 404.x1, 398.91, 402.x1 and 404.x3. (Birman-Deych et al., 2005; 
DiMartino et al., 2010; Goff et al., 2000; Richardson et al., 2010) Of these, all the HF patients 
alive on the index date and those with a diagnosis date and a membership of at least 6 months 
prior to a claim made after ‘01July2008’ for initiation of ACEI or BB as a monotherapy or in 
combination or neither of these in the Pharmacy Data File were included in the study. 
(Richardson et al., 2010) Further any patient claiming for ARB, aldosterone antagonist or 
Aliskiren in the washout period or BBs with Sympathomimetic activity (BB category 2 or 
BBC2) and any combination of BBs category 1 and 3 (BBc1 and BBc3 respectively) were 
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also excluded from the study. (Rashikh et al., 2012; Toh et al., 2012; R. Willenheimer et al., 
2004; R. Willenheimer et al., 2005) A cut-off of proportion of days (PDC) being less than or 
equal to 0.04 for each drug was chosen to define a ‘yes’ and ‘no’ for each therapeutic 
category. The details of these inclusion/exclusion criteria, cut-off criteria, prescription drugs 
and the sample characteristics can be referred in the previous study. 
Follow-up period 
 The patients were included from 1
st
 Jul 2008 till 5
th
 Jan 2011 and followed for a year of 
360 days and with consistent month duration of 30 days each. The patients were censored if 
they initiated a claim for any of the not-required drugs (ARB, BBc2, aldosterone antagonists 
or aliskiren), had a death record on the date or reached the last record from pharmacy/Quest 
Lab/Institutional/Professional Claims file or if the follow up time of 360 days was completed. 
Outcome 
 The primary outcome for this study is time-to-recurrent HF hospitalization within a year 
from the index date (date of initiation of a therapy). Recurrent hospitalization is a composite 
of all the HF hospitalization identified by the DRG codes 291, 292 and 293 and occurring 
subsequent to the index date until a year (360 days) of the index date.("National average costs 
by department for heart failure and shock," 2010; "National average costs by department for 
heart failure and shock (revisited)," 2014; Navarro-López et al., 1997; Newhouse et al., 2003) 
Thus, it includes - 
1. A subsequent hospitalization after the index date as defined in previous study as the 
first subsequent hospitalization. 
2. A new hospitalization event after the first subsequent hospitalization 
3. A change in drug status after the hospitalization and before the discharge 
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The follow up does not stop at the time an event is observed; rather this was identified as 
an event and after changing the interval the patient was followed till the time as defined 
above. The censor variable is defined for each interval rather than for the whole follow up 
time. In every interval the drug status and hospitalization status is constant. The interval 
changes with a change in either of the status. If an event is observed in an interval the censor 
variable was indicated as ‘1’ else ‘0’ and continue to follow up for next interval till last claim 
is made. For each interval a start and a stop time are defined to indicate the duration of an 
interval. Each interval censoring was assumed to be caused by covariates and 
treatment/exposure to a drug in the previous interval and the therapy initiated on the index 
date. The information was used to develop statistical models as explained later. 
A secondary outcome of these recurrent events with death as the terminal event was also 
defined. Here, censor variable was defined to indicate both the events of hospitalization and 
death with indicator of ‘1’ for hospitalization, ‘2’ for death and ‘0’ for no event or other 
reasons of censoring. 
Exposure 
A multinomial exposure variable was defined to identify exposure to either ACEI or 
BBc1 or BBc3 or a combination of ACEI with BBc1 (ABC1) or with BBc3 (ABC3) or a 
therapy other than any of these therapies on the index date and in the previous interval. The 
study used a PDC based approach as defined by Leslie and used information about 
prescription claims and days’ supply both from Pharmacy file. Each day was coded as ‘0’  
and ‘1’ based on the pharmacy claim made on a day or if the prescription was supplied for a 
day.(S. R. Leslie et al., 2008) The day the drug code ‘0’ was observed the interval was 
changed. Therefore, for the index date or for an interval the PDC is 100% on a particular 
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therapy group.  Using this technique, the exposure to the index therapy (the initiated therapy 
or trt_1), therapy in the previous interval (prdg) or in current interval (dg) was defined. 
Inverse Probability weight (IPW) 
An IPW was defined as a product of the treatment, dose and censoring weights as were 
calculated from repeated interval observations for each person-interval.(Hernán et al., 2000; 
Schaubel & Zhang, 2010; Sugihara, 2010; Van der Wal & Geskus, Sep 2011) For each of 
these individual weights a numerator and a denominator probability was calculated by using 
Proc Genmod for multinomial treatment model  for drug provided in the previous interval and 
3 multinomial  average dose (high, medium, low or none) models for ACEI, BBc1 and/or 
BBc3 for the same drug provided in the previous interval.(Faries & Kadziola, 2010) The 
Phreg models for censoring for death (Informative censoring) and other reasons for censoring 
(Non-informative censoring) were developed using count based approach.(Hernán et al., 
2004; Robins & Finkelstein, 2000; Schaubel & Zhang, 2010; Van der Wal & Geskus, Sep 
2011) Each of the numerator probability was obtained by controlling for treatment on the 
index date (trt_1), duration of days exposed on trt_1, time from the index date to start of 
current interval, dose of trt_1, treatment provided in the previous interval (prdg), days and 
dose of exposure on prdg. Along with these exposure history variables, time-fixed variables 
like gender, baseline hospitalization status and their count were defined. This was defined as 
time-fixed model.  For denominator, all the variables of time-fixed model along with a 
parsimonious model of all predictors defined at each interval for the observations from 
previous interval as time-varying covariates were controlled.  This is defined as time varying 
model. For each of these models following 2 assumptions are made: 
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 The therapy provided in each interval effects the covariates like co-
medications, cost etc. and thus varies as therapy changes with interval or time 
i.e. time-varying. 
 These time-varying covariates in an interval further affect the treatment 
provided in next interval. 
Therefore, Dose as time-varying variable was used to calculate weight for dose at each 
interval as follows(Faries & Kadziola, 2010): - 
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And the inverse probability weight (IPW) was defined as follows(Chitnis et al., 2012; 
Cole & Hernán, 2004, 2008; Hernán et al., 2000; Hernán et al., 2002; Hernán et al., 2004; 
Van der Wal & Geskus, Sep 2011): - 
     (
        
        
)  (      )  (
      
      
)  (
    
    
) 
This IPW was adjusted for history and normalized by count to adjust for sample size in 
respective treatment groups to obtain the final weight.(Chitnis et al., 2012; Hernán et al., 
2002; S. Leslie & Thiebaud, 2007)  Except for other categories of previous drug, for which 
only 11 categorical covariates were balanced w.r.t. ACEI, all other categories of drug 
provided in the previous interval showed a balance of 41-44 categorical covariates out of 44 
categorical covariates w.r.t. ACEI with final normalized IPW history weight which indicates 
a good balance amongst the treatment groups with respect to ACEI. For continuous variables 
there was still significant variation but compared to unweighted data weighing was 
considered a better approach as it balanced majority of the variation across treatment groups 
with respect to ACEI. 
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Further details of the method and time-varying covariates can be referred as explained in 
the previous study. 
Statistical Analysis 
The study develops a total time and gap model based conditional extended-cox-regression 
model to identify the time-to-recurrent hospitalization with strata across the start time of an 
interval.(Borer et al., 2012; Guo, Gill, & Allore, 2008; Lu & Liu, 2008; Robins & 
Finkelstein, 2000; Schaubel & Zhang, 2010) It was assumed that all the recurrent events are 
different from each other. The results were compared with unweighted and univariate model 
for person-interval data. A univariate Kaplan Meier curve, Schoenfeld residuals and log rank 
test were developed to test the proportionality hazard assumption, which was violated in this 
study (p-value ≤ 0.05).   
For secondary outcome, a marginal model was developed which assumes a patient is at 
risk of all these different events i.e. hospitalization and mortality at all the times. All the 
conditional models and marginal models were modified to obtain robust standard errors and 
to indicate correlated observations for each patient using COV(Aggregate) weighted for 
history of the treatment, dose and likelihood of censoring using IPW weight as explained 
above.   
In these models, a patient was followed for the duration as long as the patient is on one of 
the either treatment groups with or without switching to represent the effect of censoring in 
current interval w.r.t. the effect of therapy provided on the index date i.e. ‘Initiated Therapy’ 
(trt_1). A univariate model to test the effect of trt_1 was also developed for all the models. 
Additionally, the therapy provided in the previous interval (prdg) was also included in the 
fully adjusted models along with other fixed-effect and time varying covariates as used for 
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IPW weights. None of the models controlled for the effect of current therapy on current 
interval censoring to avoid the possibility of reverse causation bias. 
For reference purpose, models were numbered as ‘1’ for univariate unweighted crude 
model, ‘2’ for weighted univariate total time model, ‘3’ for the weighted fully adjusted total 
time model, ‘4’ for weighted univariate gap time model, ‘5’ for the weighted fully adjusted 
gap time model, ‘6’ for weighted univariate marginal model, ‘7’ for the weighted fully 
adjusted marginal model.  
All analyses were performed using Statistical Analysis Software (SAS) version 9.3 (SAS 
Institute Inc., Cary, NC, USA) with a significance level defined at p-value ≤ 0.05.  
Sensitivity analysis for Change in length of follow-up 
As discussed in the previous study, results were re-analyzed for change in follow-up time 
period from 1-year to 2-years based on past literature suggestion of the effect of length of 
follow-up on estimates.(Sliwa et al., 2004), (R. Willenheimer et al., 2005) 
Subgroup analysis of Ejection Fraction (EF) 
Here, patients with EF <45% were identified using a claims-based definition based of 
systolic dysfunction and with a positive predictive value of 87%.(Setoguchi et al., 2011) 
According to this definition patients were chosen with no diagnosis of atrial fibrillation (ICD-
9-CM code 427.31) and the ones who had received Digoxin during the 180 days before the 
index date, which for this study is the therapy initiation date.(Jensen et al., 2012; Setoguchi et 
al., 2011)  
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Results 
There were 331 (5.15%) events of recurrent hospitalizations in the cohort of 6430 elderly 
HF patients. At interval level these observations gave 18923 person-interval observations in 
the cohort with 1.75% of event intervals of recurrent hospitalization. Of all the patients 55 
patients (0.86% patients) observed more than one hospitalization events representing a rare 
event i.e. 0.29% interval observations only. Along with this there were 695 events which 
constitute 10.81% of cohort patients and 3.67% of person interval observations. Table 1 
compares the frequency distribution of censored observations in the person-interval cohort. 
There were 55 recurrent events with ≥2 counts of hospital events i.e. 0.86% of all the cohort 
population at the patient level. 
The Kaplan-Meier plot for unadjusted unweighted person-interval data is represented in 
Fig 2.  This represents maximum survival probability for patients initiating ACEI and lowest 
for BBc3 groups at different stop points where interval ends. Although all the treatment 
groups appear to be somewhat proportional to the survival curve of ACEI for initial part of 
the data, but log rank test violates the proportionality hazard assumption for at least one 
treatment group (p-value<0.001).  
Table 2 compares the result of all the Hazard Ratios from all the models and their 
respective 95% Confidence Interval for the risk of recurrent hospitalization. The result 
demonstrates that after adjusting for other covariates in Model 3 or Model 5 i.e. Total time 
and Gap Model, initiation on BBc1 and BBc3 gave a non-significant hazard ratio with respect 
to ACEI. The hazard ratio for BBc1 were 0.969(95%CI: 0.47- 1.399) and for BBc3 were 
1.32(95%CI: 0.702- 2.483) from both the Models. The hazard ratios for combination therapy 
of BBc1 and ACEI was 0.953(95%CI: 0.457- 1.988) and it was 0.533(95% CI: 0.19- 1.496) 
 125 
 
for a combination of ACEI and BBc3 from both the models. It is to be noted here that all the 
results from total time and gap model were exactly same when stratified across start time 
from index date. This could be probably because they both are representing the same interval 
when stratified by start time for an interval from the index date. 
For marginal model which models the risk of recurrent hospitalization with death as the 
terminal event, the hazard ratio for BBc1 was 0.871(95%CI: 0.512- 1.482), for BBc3 was 
1.41(95% CI: 0.843- 2.36), for combination of ACEI and BBc1 was 0.77(95%CI: 0.431- 
1.376) and for combination of ACEI and BBc3 was 1.407(95%CI: 0.53- 3.736). 
For other therapy group, all the models represented significantly high hazard ratios 
compared to ACEI except for the univariate unweighted crude model.  
Table 3 presents the result of sensitivity analysis for 2 year follow up data. Contrary to 1-
year follow-up data, this data gave significant p-values of BBc3 as monotherapy for both 
recurrent hospitalization and also for composite outcome of recurrent hospitalization with 
death as terminal event. The respective HR values were 2.256(95%CI: 1.154- 4.413) and 
1.933(95%CI: 1.135- 3.295). For BBc3 as monotherapy also respective estimates increased 
compared to 1-year data. These HR estimates for recurrent hospitalization and for composite 
outcome were 1.132(95%CI: 0.511- 2.507) and 2.097(95%CI: 0.967- 4.55) respectively. For 
BBc1, the increment was within the 95%Confidence interval of 1-year data. The HR 
estimates for BBc1 as monotherapy were 1.265(95%CI: 0.698- 2.292) and 1.102(95%CI: 
0.647- 1.877) for the 2 outcomes respectively. And they were 0.532(95%CI: 0.253- 1.119) 
and 1.079(95%CI: 0.611- 1.905) respectively for each outcome for BBc1 as combination 
therapy with ACEI. 
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Discussion 
The above results indicate a non-significant recurrent hospitalization of BBc1 compared 
to ACEI. These estimates decreased for all the models, i.e. Total time, Gap time and also for 
Marginal model after adjustment. 
The CIBIS III trial reported a slightly non-significantly high HR of 1.25 (95%CI: 0.87-
1.81) for WHF while hospitalized for bisoprolol compared to ACEI.(R. Willenheimer et al., 
2005) As argued previously, recurrent hospitalization can be considered a measure of WHF, 
the 2 results seem to have overlapping 95%CI estimates. The results also indicate that the 
marginal event estimates for composite outcome, i.e. for recurrent hospitalization with death 
as the terminal event, the estimate is slightly low with slightly narrow confidence interval. 
This may probably imply that the greater benefit of BBc1 lies in not just reducing the risk of 
recurrent hospitalization but it reduces overall risk of hospitalization with death as the 
terminal event and thus shows a promising therapy in comparison to ACEI. This could 
possibly be attributed to the ample evidence in favor of BBs being a preferable therapy to 
reduce SCD. 
For BBc3, all the univariate models (1, 2, 4 and 6) gave a significantly high hazard ratio. 
However, with adjustment for covariates from the previous interval total time and gap model 
estimates were non-significant but slightly high compared to BBc1. The CARMEN trial did 
not presented any HR values but reported the 10% and 8% cases of worsening of CHF for 
patients on BBc3 and its combination with ACEI respectively as opposed to 10% cases for 
ACEI group, which similar to our study implies a no significant difference in estimate for 
BBc3 compared to ACEI.(Komajda et al., 2004) Surprisingly, these estimates again became 
significant in the sensitivity analysis indicating deterioration in their effect for the 2-year 
data. These estimates were worse than any of the BBc1 estimates in the second year 
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rendering BBc3 as the therapy as an ineffective treatment at least as monotherapy. It is 
important here that none of the estimates of BBc1 in this 2-year data were higher than any of 
the BBc3 as monotherapy or as combination estimates for the 2-year data and as BBc3 
monotherapy for 1-year data. 
For both the combination therapies the hazard of recurrent hospitalization was non-
significantly different than ACEI. As expected the combination of BBs with ACEI gave low 
hazard ratio of recurrent hospitalization with more favorable results for combination of ACEI 
and BBc3 for 1-year data. However, these estimates although non-significant but they 
became unexpectedly high for the 2-year follow up data, which raises doubt regarding the 
utility of BBc3 even as a combination.  
Overall, it appears that BBc3 has a better protective effect as combination therapy only 
for 1-year data followed by BBc1 as monotherapy or as combination. This leads us to 
recommend BBc3 combination with ACEI for better protection for the first year as also 
suggested by past literature.(Sliwa et al., 2004)  However, the study does not support its long 
term utility, for which BBc1 appears to be a better alternative. Additionally, considering the 
estimates of BBc1 as monotherapy and as combination are close enough for the both years, it 
could be considered advisable to prescribe BBc1 as monotherapy rather than combination to 
avoid polypharmacy amongst elderly patients and for long term effect.(Fahey et al., 2005; 
Gupta & Aparasu, 2013; Powlson, 2003; Volpe et al., 2010) 
For the secondary outcome i.e. composite outcome of recurrent hospitalization with death 
as the terminal event also all the BB groups gave non-significant hazard ratios with respect to 
ACEI. Whereas for BBc1 as monotherapy and as combination with ACEI it was non-
significantly low; for BBc3 group it was non-significantly high, being highest for BBc3 as 
monotherapy. Therefore, for this composite outcome, it appears that although it could be a 
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non-significant difference nevertheless BBc1 as monotherapy or as combination both appears 
to be more beneficial compared to BBc3 as monotherapy or as combination. This seems 
justifiable because in one of our previous studies it was observed that a higher risk of 
mortality was observed for BBc3 as combination and as monotherapy compared to BBc1 as 
monotherapy or as combination. Additionally, the results of sensitivity analysis gave 
statistically significant high hazard ratio for BBC3 as monotherapy and non-significantly 
high HR values for BBc3 as combination therapy. 
Although CARMEN trial did not reported a HR for all-cause mortality or all-cause 
hospitalization, but they reported non-significant p-values for BBc3 (0.8403) and for its 
combination(0.5875).(Komajda et al., 2004) The CIBIS III trial on the other hand reported a 
HR of 0.94 (95%CI: 0.77-1.16) for intention-to-treat analysis and a HR of 0.97 (95%CI: 
0.78-1.21).(R. Willenheimer et al., 2005) The estimate from this study is slightly low for 
BBc1 with an HR of 0.871(95%CI: 0.512- 1.482) compared to CIBIS III trial estimate 
possibly because along with all-cause mortality the composite outcome in this study is 
specifically for HF hospitalization and not any cause hospitalization as is the case in the trial. 
Additionally, the composite outcome used in both these trials is not a representation of 
correlated repeated hospitalization; rather it counts either of the events with equal risk. This 
study thus provides estimates from different viewpoints as expected in real world. 
In one of our previous studies, where hazard of first subsequent hospitalization was 
analyzed, BBc1 as monotherapy was suggested as a preferable therapy. Compared to this 
study, current study demonstrates that although for BBc1 as monotherapy the hazard of first 
hospitalization is low compared to BBc3, but for subsequent recurring hospitalizations the 
hazard increases slightly for monotherapy and majorly for combination of ACEI and BBc1. 
The hazard ratios for all the outcomes from both the studies are represented in table 4. From 
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these results, it is clear that BBc1 as monotherapy is a considerably more protective therapy 
for first hospitalization. The combination of BBc1 with ACEI, on the other hand seems to be 
more beneficial for mortality and for composite outcome i.e. for risk of hospitalization with 
death as the terminal event. For these 2 latter events, as monotherapy also, BBc1 appears to 
be doing a good job. And thus especially among elderly patients to avoid polypharmacy, 
BBc1 as monotherapy for mortality or for composite outcome can be expected to provide 
appreciable estimates along with reduction in risk of first hospitalization as already 
suggested. Further, the BBc3 as combination seems to be a therapy of choice for reducing the 
risk of recurrent hospitalization just for 1-year follow up. For first hospitalization also it 
seems to have done an appreciable job compared to monotherapy, but it definitely gives the 
impression of being a non-preferable therapy for mortality and for composite outcome.  This 
contradicts the result of the COMET trial, which as suggested previously reported a greater 
reduction in fatal and non-fatal MIs and SCD due to carvedilol (BBc3) treatment compared to 
metoprolol treatment (BBc1).(Poole-Wilson et al., 2003) The possible difference could be 
due to the fact that the COMET trial included severe patients with EF<35% which as 
suggested in previous study constitutes a very small proportion of patients in this 
study.(Poole-Wilson et al., 2003) This possibility is supported by the fact that in subgroup 
analysis i.e. amongst patients with EF<45% more BBc1 users showed recurrent events 
compared to BBc3 users. There were 27.78% of BBc1 users compared to 11.11% of BBc3 
users with recurrent events from amongst overall 18 events. 
In real life, however, recurrent hospitalization is not observed as an event independent of 
the risk of death as the terminal event, which means there is always an existing risk of a 
composite recurrent hospitalization which is associated with death as the terminal event.(Lu 
& Liu, 2008; Schaubel & Zhang, 2010) Even with first hospitalization, recurrent 
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hospitalization and death seems to be associated at all points during follow up. This implies 
that BBc1 as combination therapy with ACEI or as monotherapy is a promising Beta-Blocker 
compared to BBc3. Further research in this direction shall validate the findings. 
For other therapies, except for the univariate unweighted model (Model 1), all other 
models gave a significant high hazard ratio. However, since this group contains maximum 
variation in terms of exposure groups included another variables which remained unbalanced 
even after weighing, the estimates could be unreliable. However, considering that this group 
is not the focus of this study, the results are not being discussed here. 
Limitation  
The limitations of this study are same as discussed elsewhere. This includes coding issues 
inherent to claims data, lack of direct measure of severity and random assignment to different 
treatment groups, and no discrimination of ACEI vs BB vs their combination as first line or 
2
nd
 line or 3
rd
 line therapy and the study included only JNC approved drugs.  
In addition to this there is a measurement of exposure assumed proportionally the same in 
all the treatment groups. For example, due to insufficient follow-up time for these patients, a 
non-differential measurement of exposure can be possibly observed. May be all the therapies 
are in the therapy-initiation phase and have not reached proper maintenance dose, especially 
prevalent effect for BB-therapy. To avoid this, patients were followed for a defined period 
based on past literature. The effect of strictly including patients who took the drug for at least 
14 days in model 5 also assures some time on these therapy before their results can be 
compared. Additionally a sensitivity analysis was done to assess the effect of longer follow-
up period.   
 131 
 
The study could not provide the effect of BBs with sympathomimetic activity i.e. BBc2, 
effect of actual adherence and the effect of some important covariates like race. These should 
be the focus of future studies before generalizing the results to all the elderly HF patients. 
Strength 
1. Unlike many other observational studies, this study controls for the influence of dose 
too along with other variables. The CIBIS III trial used an open design where the 
titration schedule was dependent on the tolerability of each individual and their 
response to treatment.(R. Willenheimer et al., 2004) In real life, this situation is the 
driving factor for switching of the therapies. 
2. It provides information for ACEI/BB as monotherapy and as combination both, and 
not just of monotherapy. In CIBIS III trial, the author suggested that the first initiated 
therapy like ACEI or BB, stands the better chance to be given for a long term and in 
adequate dose.(R. Willenheimer et al., 2004) However, our study has included 
patients on each therapy with doses as prescribed in real world. In real-world doses 
are adjusted as per the tolerability of the patient and thus their up-titration may be 
different than that applied in a controlled environment of an RCT. For example, here 
already a minimum tolerable limit and optimum standard dose is known, so 
prescribers may have a different starting dose compared to that used in a RCT.  
3. Sensitivity analysis tests the results for initiating ACEI/BB/combination therapies for 
a longer duration, which is essential as suggested by previous trials for BBs to show 
their optimum effect(Sliwa et al., 2004; R. Willenheimer et al., 2005). 
4. The use of available lab values at various time points minimizes the confounding by 
indication. Although there are lots of missing information in these variables, but this 
is expected as also suggested by Schneeweiss.(Schneeweiss et al., 2012) Further using 
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LOCF, these possibilities of missing values was reduced. Weighing the history of the 
observation also helped to reduce the effect of missing information. And finally, any 
missing observation was not discarded from the study; rather it was included as a 
‘Missing value’ category to extract whatever possible information could be found 
from the study. 
5. The class effect of different BBs has been compared here, which is difficult in RCTs. 
This provides additional information to clinicians which look out for therapeutic 
equivalent drugs to replace one. 
6. The study provides evidence for all types of HF patients and not just those with LVEF 
<35% as chosen in CIBIS III trial.(R. Willenheimer et al., 2004) As already stated, 
beta-PRESERVE trial is trying to target effect of using BBs in HFNEF patients too, 
our study provide some evidence with regard to those population and may support the 
need for the trial for all types of population for HF and thereafter may result in the 
modification of the guidelines.(Zhou et al., 2010) 
7. With double weighting and Covs(aggregate) the complex nature of the treatment was 
incorporated in the study since patients are provided certain treatment by considering 
their possibility of death/switching/other causes of drop-outs as the terminal event and 
also by considering that measures on one person are correlated in nature. This helps to 
bring the data and its analysis close to reality. 
8. The Inverse probability weights helped to balance various treatment groups for at 
least the categorical covariates with respect to the reference category, thereby 
strengthening the causal design. 
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9. By comparing the results of recurrent event with models of recurrent event 
considering death as the terminal event, a comprehensive comparison of the effect of 
the treatment has been provided. 
10. Further, use of multiple controls like other therapies along with nested nature of the 
data in the switching count process model helps to control for any overt bias. For this 
model, results are also obtained by cross-comparison across same patient on different 
treatment which provides advantages similar to cross-over designs along with cohort 
population. 
11. The use of strong operational definition of exposure on the index date and in the 
previous interval based on 100% persistence on a day or in an interval respectively is 
a major strength of the study. However, it does not confirm the actual compliance to a 
therapy. Despite that the current definition are good method of intention-to-treat 
analysis with 100% persistence rate on a day or in an interval. 
The strength of this study is evident from the closeness of the findings with the trial. 
Additionally some new estimates were assessed here which were not studied previously. 
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Conclusion 
The results indicate that compared to ACEI there is a possible statistically non-significant 
effect of BBs both as monotherapy and as combination. BBc1 seems to be a preferable 
therapy compared to BBc3 for first hospitalization, for composite outcome of recurrent 
hospitalization with death as the terminal event and for mortality as an independent event. On 
the other hand, BBc3 as combination rather than BBc1 appear to be more beneficial for 
recurrent hospitalization as a measure of WHF for 1-year follow-up after which it’s effects 
seem to deteriorate considerably in favor of BBc1 as combination or even as monotherapy 
and ACEI. 
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Appendix 
Fig 1 Study Design 
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Fig 2.  Kaplan-Meier Plot for univariate unweighted survival probabilities for recurrent hospitalization after initiating a treatment 
on the index date for person-interval data 
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Table 1. Censored observations in the interval level cohort  with death as the terminal event 
Recur Frequency Percent 
0 17566 84.04% 
1 (Hospitalization) 331 1.75% 
2 (Death) 695 3.67% 
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Table 2. Comparison of Hazard Ratios for recurrent hospitalization due to initiation therapy across Models 1 to 7 HR(95% CI: 
Lower CI-Upper CI) 
Obs Initiated Therapies HR1 HR2 or HR4 HR3 or HR5 HR6 HR7 
1 BBc1: BBs 
1.143 
( 0.824- 1.585) 
1.043 
( 0.658- 1.655) 
0.969 
( 0.47- 1.996) 
0.985 
( 0.693- 1.399) 
0.871 
( 0.512- 1.482) 
2 BBc3: Combined alpha and BBs 
2.442 
( 1.704- 3.498) 
2.051 
( 1.274- 3.302) 
1.32 
( 0.702- 2.483) 
1.719 
( 1.133- 2.607) 
1.41 
( 0.843- 2.36) 
3 Combined ace and BBc1 
1.052 
( 0.588- 1.88) 
0.81 
( 0.381- 1.719) 
0.953 
( 0.457- 1.988) 
0.846 
( 0.477- 1.502) 
0.77 
( 0.431- 1.376) 
4 Combined ace and BBc3 
1.237 
( 0.592- 2.585) 
1.376 
( 0.567- 3.342) 
0.533 
( 0.19- 1.496) 
2.079 
( 0.839- 5.156) 
1.407 
( 0.53- 3.736) 
5 Other Therapies 
0.823 
( 0.599- 1.13) 
18.473 
( 11.419- 29.885) 
6.925 
( 3.151- 15.218) 
14.679 
( 9.927- 21.705) 
6.311 
( 3.694- 10.78) 
 
HR1 = Hazard ratio for Univariate Unweighted Count Model with switching (Model 1) 
HR2 and HR4 = Hazard ratio for Weighted Univariate Model with switching– a total time or a gap model  
(Model 2 and 4 respectively) 
HR3 and HR5 = Hazard ratio for Weighted Adjusted Model with switching- a total time or a gap Model (Model 3 and Model 5 respectively) 
HR6 = Hazard ratio for Weighted Univariate Marginal Model with switching (Model 6) 
HR7 = Hazard ratio for Weighted adjusted Marginal Model with switching (Model 7) 
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Table 3.  Sensitivity Analysis for 2-year data. 
Hazard Ratios for all the HF hospitalization outcomes for BBs as monotherapy or as combination therapy with respect to ACEI 
Drug First hospitalization Recurrent 
hospitalization 
Composite outcome Mortality 
BBc1: BBs 0.971( 0.473- 1.994) 1.265( 0.698- 2.292) 1.102( 0.647- 1.877) 0.369( 0.023- 6.001) 
BBc3: Combined alpha and BBs 1.303( 0.688- 2.465) 2.256( 1.154- 4.413)* 1.933( 1.135- 3.295)* 1.882( 0.095- 37.089) 
Combined ace and BBc1 0.94( 0.449- 1.965) 0.532( 0.253- 1.119) 1.079( 0.611- 1.905) 0.000 
Combined ace and BBc3 0.536( 0.19- 1.509) 1.132( 0.511- 2.507) 2.097( 0.967- 4.55) 4.4( 0.28- 69.249) 
* Significant at p-value ≤0.05 
 
 
Table 4. Hazard Ratios for all the HF hospitalization outcomes for BBs as monotherapy or as combination therapy with respect to ACEI 
Drug First hospitalization Recurrent 
hospitalization 
Composite outcome Mortality 
BBc1: BBs 0.562 ( 0.278- 1.134) 0.969 ( 0.47- 1.996) 0.871 ( 0.512- 1.482) 0.212 ( 0.028- 1.598) 
BBc3: Combined alpha and BBs 1.242 ( 0.636- 2.426) 1.32 ( 0.702- 2.483) 1.41 ( 0.843- 2.36) 1.069 ( 0.107- 10.701) 
Combined ace and BBc1 1.052 ( 0.409- 2.706) 0.953 ( 0.457- 1.988) 0.77 ( 0.431- 1.376) 0.000 
Combined ace and BBc3 0.632 ( 0.223- 1.793) 0.533 ( 0.19- 1.496) 1.407 ( 0.53- 3.736) 1.316 ( 0.115- 15.122) 
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Conclusion 
The results indicate that - 
1. Compared to ACEI there is a possible statistically non-significant effect of BBs both 
as monotherapy and as combination.  
 
2. BBc1 seems to be a preferable therapy compared to BBc3 for first hospitalization, for 
composite outcome of recurrent hospitalization with death as the terminal event and 
for mortality as an independent event.  
 
 
3. BBc3 rather than BBc1 seems to be more beneficial for recurrent hospitalization as a 
measure of WHF especially for patients with EF<45%. For general population as 
included in this study, BBc3 appear to be more beneficial for recurrent hospitalization 
as a measure of WHF just for 1-year follow-up after which it’s effects seem to 
deteriorate considerably in favor of both ACEI and BBc1 as combination or even as 
monotherapy. 
 
Final statement wrapping up the dissertation document 
BBs have statistically non-significant risk of HF hospitalization in comparison to ACEI 
among elderly HF patients with more beneficial effects obtained for patients initiating BBc1 
rather than BBc3 for a cohort of patients which includes majority of patients with normal EF 
i.e. patients with mild or moderate HF.  
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